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Abstract
In various neurodegenerative diseases, including Alzheimer’s disease, progressive
supranuclear palsy, Pick’s disease, and corticobasal degeneration, the deposition of fibrils
composed of misfolded tau protein is observed. Recent evidence suggests that tau fibrils
transfer between cells and spread throughout the brain, underscoring the significance of
fibril propagation.
Six tau isoforms exist in the adult human brain that can be grouped into 4-repeat
(4R) tau and 3-repeat (3R) tau based on the presence or absence of the second of four
microtubule binding repeats.

We demonstrate in vitro that seeded fibril growth, a

prerequisite for the spreading of the tau pathology, is crucially dependent on the isoform
composition of individual seeds. Seeds of 3R tau and 3R/4R tau recruit both types of
isoforms. Seeds of 4R tau recruit 4R tau, but not 3R tau, establishing an asymmetric
barrier. Conformational templating of 4R tau onto 3R tau seeds eliminates this barrier,
giving rise to a new type of tau fibril.
Tau fibrils formed in vitro routinely utilize polyanionic molecules as cofactors to
stimulate nucleation. A broad set of negatively charged cofactors, including nucleic
acids, polypeptides, and glycosaminoglycans were applied to induce fibril assembly.
Utilizing electron paramagnetic resonance (EPR) spectroscopy, we found that the core
structure of the fibril is conserved, regardless of cofactor used.

Additionally, we

assessed whether a cofactor provides a role in tau aggregation beyond inducing the initial
ii

nucleation events, and observed that the presence of a cofactor is needed for fibril
propagation to be sustained. The cofactor-fibril interaction was investigated, revealing
that cofactors are bound to the fibril and that the basis of the interaction is electrostatic.
Cofactor binding is dynamic, as introduction of an alternative cofactor was shown to
result in exchange with the bound cofactor.
Protein misfolding cyclic amplification (PMCA) is a tool used for the detection of
dilute concentrations of prion fibrils. We have successfully applied this concept towards
the amplification of tau fibrils for the first time and demonstrated that fibrils can be
amplified, even when diluted by several orders of magnitude.
These findings provide basic mechanistic insights into the seeding, propagation,
and diversification of tau fibrils. Importantly, we demonstrate that cofactors are not only
of consequence for inducing nucleation events, but decorate the fibril and provide a
critical role in fibril propagation.
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Chapter 1: Introduction
1.1 Protein misfolding and amyloids
1.1.1 Misfolding and disease
The 3-dimensional structure of a protein has been shown to be governed by its
primary structure (1, 2). While linear strands of most proteins fold into highly structured
native states, there are also proteins whose native states are devoid of structure in large
regions or the entirety of the protein and are considered to be intrinsically disordered (3).
The association of disordered proteins with various neurodegenerative diseases has been
well documented, with aggregated forms of the natively disordered protein found
accumulated in the form of fibrillar aggregates (4, 5). Among these disordered proteins is
the microtubule-associated protein tau (6, 7) that is found deposited as misfolded
aggregates in Alzheimer’s disease brain.

The appearance of these aggregates has

instigated an effort to better understand the structure of aggregates as well as the
mechanisms responsible for their initiation and growth.
Protein aggregation is the result of a protein misfolding to a conformation other
than its native soluble state. For folded proteins it has been suggested that the main event
leading to aggregate formation is the destabilization of the native state, which results in
an unfolded intermediate that is then more prone to aggregation (8, 9). As intrinsically
disordered proteins already lack secondary or tertiary structure, the process of unfolding
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is not required and instead the already unfolded protein can switch more directly to the
conformation of the aggregate.
Protein misfolding is a common event that can have deleterious consequences.
Within the cell there exist corrective mechanisms to ameliorate the effects of misfolded
proteins, namely the recognition and degradation of the potentially harmful conformation
through the proteosome (10) or the intervention by the chaperone system that allows a
misfolded conformation to fold properly (11, 12).

Misfolded proteins that are not

remedied can pose serious risks to the cell and provide the basis of any one of a number
of diseases referred to as protein conformational disorders (13).

How a misfolded

conformation can induce a harmful effect is not entirely understood and may vary
according to disease and disorder. A general paradigm is that misfolded proteins can
contribute to the disease pathogenesis by providing a toxic gain of activity (i.e. the
misfolded protein is toxic) or that the harmful effect stems from a protein losing its
natural function as a consequence of misfolding. For misfolded conformations that lead
to intermolecular associations and aggregation, it is possible that the protein aggregates
produce the toxic gain or loss of function that is witnessed in disease (4, 13). Although
the causative link of these aggregates to the progression of disease is not conclusive, the
appearance of these protein aggregates has warranted extensive investigation
nevertheless.
1.1.2 Amyloid structure of aggregates in disease
The deposition of aggregates containing misfolded proteins is observed in
numerous neurodegenerative diseases other than Alzheimer’s disease, and includes
Parkinson’s disease, and Huntington’s disease, Amyotrophic lateral sclerosis, as well as
2

the transmissible spongiform encephalopathies (14).

Common to all these protein

aggregates is a conserved amyloid structure (14) and a fibrillar morphology (15, 16).
Structurally characteristic of amyloid fibrils is a conserved cross -structure, in which
fibrils are composed of stacked protein strands hydrogen bonded as -sheets and aligned
perpendicular to the long axis of the fibril (17, 18). Additionally, different amyloids
share a general property used for their structural identification, namely the ability to bind
and enhance the fluorescence of dyes such as thioflavin T and thioflavin S (19). As to the
specific composition of amyloids, the protein involved varies considerably depending on
disease. In Alzheimer’s disease, proteins of tau and amyloid-beta (A) are observed as
amyloid deposits (20), while in Parkinson’s disease and the spongiform encephalopathies,
amyloids are composed of α-synuclein and prion proteins, respectively (14). Despite the
potential to form a conserved structure, the proteins found to assemble into amyloids
have no general sequence homology, nor any overall resemblance in native structure (14,
21). The general paradigm of amyloid aggregation was that the occurrence was rare and
was only specific to a small group of proteins (around 20) that were found to assemble
into such structures observed in disease.

However, the SH3 domain of

phosphatidylinositol 3-kinase, and acylphosphatase—proteins whose aggregation is not
observed in disease—were shown to be capable of forming amyloid aggregates under
non-physiological conditions (22, 23).

Furthermore, myoglobin, a well-structured

globular protein that lacks -sheets in its native state, was induced to form fibrillar
aggregates under specific conditions (24). It is believed that almost any protein possesses
the capacity to form amyloid fibrils, given the right environmental conditions (23).

3

1.1.3 Model of amyloid formation
The pathway that describes the conversion of the monomeric protein or
polypeptide species into their assembled amyloid counterparts has long been considered
crucial for the therapeutic intervention of amyloid diseases. Despite decades of research,
however, a comprehensive and generally accepted mechanism that describes the stepwise assembly of amyloid fibrils has remained elusive (25, 26).

The course by which

intra and intermolecular associations occur towards the polymerization of fibrils proceeds
via a nucleation dependant mechanism (27, 28).

Observations of the kinetics of a

polymerization reaction reveals a long lag phase where little or no assembly is shown to
occur, followed by a dramatic acceleration and then gradual plateau of amyloid growth
(Figure 1.1). The events related to the lag phase are not fully understood, but are defined
by the time required for nucleation to occur. Nucleation of fibrils during the lag phase
can be divided into two general processes described as primary or secondary nucleation
(29, 30). Primary nucleation involves the conversion of monomer into nuclei that are
competent for fibril growth, while secondary nucleation can be attributed to fibril
breakage that leads to additional nucleation competent species (more fibril ends) (29-31).
Explanations for the events preceding the formation of competent nuclei range from
conformational rearrangements of monomers and the intermolecular assemblies of
monomers into oligomeric species (25-27). In the case of oligomer formation it is
thought that the successive assembly of monomers occurs until nuclei are formed that are
capable of adding monomers to form a fibril. Once the nuclei are formed, the addition of
monomers will proceed to elongate fibrils, presumably by the addition of monomer at the
ends of the fibrils. As the lag phase leading up to the elongation phase is dependent on
4

the slow formation of nuclei (29), the introduction of competent nuclei would be
expected to bypass the nucleation event and lead directly to the elongation of the fibril.
This phenomenon is observed when preformed fibrils are added to monomers as seeds,
resulting in the abolishment of the lag phase and the direct induction of fibril growth (27,
28).

Figure 1.1: Aggregation kinetics of amyloids. Observed in the aggregation of
amyloids is a lag phase which is dependent on the time required for nuclei to form.
Nucleation is a prerequisite for fibril growth, and can be circumvented by the addition of
fibril seeds.
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1.2 Tau and disease
1.2.1 Tau aggregates are found in disease
Alzheimer’s disease is form of dementia that is estimated to affect up to 24
million people worldwide (32). In Alzheimer’s disease there are two fundamental
pathological hallmarks that are observed in the diseased brain. Lesions of aggregated
material are found both extracellularly as neuritic plaques and intracellularly as
neurofibrillary tangles (NFTs) (20, 33). The chief component of neuritic plaques was
identified as amyloid aggregates composed of A protein (34, 35). Studies focusing on
the intracellular NFTs revealed an abundance of fibrils composed of paired helical
filaments that were capable of being stained with congo red dye, which like A suggested
an amyloid structure (36). The proteinacious composition of these NFTs began to be
elucidated when it was shown that antibodies to tau were also selective to neurofibrillary
tangles (37).

Furthermore, antibodies to fibrils are selective to tau and vice versa,

suggesting that the fibrils in NFTs contain tau (38, 39). The finding that the protein
purified from NFT derived fibrils shared the amino acid sequences found in tau
confirmed that the fibrils are in fact composed of tau (40). Importantly, the prevalence of
lesions composed of tau is not specific to just Alzheimer’s disease, as tau lesions are
found in other neurodegenerative diseases and disorders as well. Combined there are
more than 20 diseases besides Alzheimer’s where tau lesions are central to the pathology,
termed tauopathies, and include progressive supranuclear palsy, Picks’s disease,
coricobasal degeneration, and Down’s syndrome (41, 42).
The protein composition of fibrils has long been known, but what role the fibrils
play in disease is not well understood. For instance, in what manner the fibrils are
6

responsible for the progression of disease has been a matter of debate. Alternative
perspectives of the impact of tau fibrils even speculate that the fibrils could provide a
protective role by recruiting and therefore reducing species that are toxic to the cell (43).
While the specific role of tau species in disease is not known, the contribution of tau
towards disease has been verified by genetic data. In frontotemporal dementia and
Parkinsonism linked to chromosome 17 (FTDP-17), mutations in the tau gene have been
implicated to disease suggesting a hereditary basis. Additionally, tau gene mutations have
been linked to an increase in risk of developing other tauopathies including Pick’s disease
and progressive supranuclear palsy (41). Combined, these cases linked to tau gene
mutations indicate that tau dysfunction can be attributed to disease. Evidence that links
tau fibrils to disease includes the observations that the distribution of NFTs is not
random, but can be differentiated into six successive stages known as Braak stages. Also,
the advanced Braak stages observed occur with concomitant cases of dementia (44).
Further evidence that indicates a relationship between tau fibrils and disease include the
observation that the severity of dementia caused by Alzheimer’s disease correlates with
the amount of NFTs present (45). These findings have helped to shed light on the disease
pathology and suggest that tau fibrils contribute to disease progression.
1.2.2 Tau fibril propagation
Tau fibrils have been associated with the development of disease, and therefore it
is important to better understand the mechanisms behind the misfolding of monomeric
tau into fibrils. The aggregation of monomeric tau into fibrils was suggested to occur
through a nucleated assembly mechanism. With the addition of fibrils formed in vitro or
extracted from Alzheimer’s disease brain, monomeric tau can be recruited onto fibril
7

seeds (46). In another study it was shown that monomeric tau elongated on fibril seeds
and adopted the conformation of the seed in a templated mechanism (47).

Earlier

paradigms regarding the tendency of tau to misfold and form fibrillar aggregates
proposed the event to occur autonomously in cells and therefore the effect that fibrils
could have on neighboring cells was not thought to be of great importance (48). With
recent findings it has been proposed that tau fibril formation may not occur independently
within each cell, but that fibrils having nucleated in one cell could propagate and spread
to neighboring cells. The ability of fibrils to recruit monomer when introduced to cells
was shown by Nonaka et al. when fibrils transfected into cells overexpressing tau
resulted in the aggregation of the endogenous monomer (49). Additionally, Frost et al.
demonstrated that tau aggregates are capable of being taken up by cells; that intracellular
aggregates can transfer between co-cultured cells; and that once cells are transfected with
tau aggregates, the misfolded state is propagated in the endogenous tau population (50).
In other studies it was shown that cells are capable of internalizing fibrils and that the
endogenous tau is recruited as aggregates resembling NFTs (51, 52).

When

characterizing the tau species that are internalized by cells it was revealed that small
aggregates and short fibrils (10-100 µm) are taken up while monomer and larger fibrils
are not (53).
Propagation of tau fibrils and the misfolded tau pathology has also been
demonstrated in the brains of mice. When insoluble extract containing fibrils from the
mouse brain was injected into healthy mouse brain, the healthy mouse’s brain developed
a fibrillar tau pathology that spread from the site of injection (54). Similarly, when brain
extracts from humans who had died from various tauopathies was injected into mouse
8

brain, the formation of tau lesions was induced (55). In other mouse models, pathogenic
misfolded tau originating in the entorhinal cortex has been shown to spread to
neighboring brain regions resulting in the aggregation of the local monomer (56, 57).
From these findings it is clear that the propagation of tau fibrils is not limited to
the cell or brain region of origination, but instead tau fibrils are found to spread
intercellularly via undefined mechanisms. From cell and animal models it has been well
established that misfolded tau in the form of fibrils can exert profound effects when
introduced, as the misfolded state of the fibril can be passed onto the endogenous tau
population.
1.2.3 Structure of fibrils
Investigation of the structural features of tau aggregates reveals a commonality to
amyloid structures, as tau fibrils also possess an ordered cross- structure. The spacing
between the stacked strands perpendicular to the long axis of the fibril occurs every 4.7 Å
(58) (Figure 1.2A). Analysis of tau fibrils (Figure 1.2B) by electron microscopy and
atomic force microscopy reveal tau fibril structure is actually diverse, with variations
observed with respect to fibril width and twist periodicity (59). While atomic resolution
structures have yet to be elucidated, studies using in vitro formed fibrils indicate that the
 strands of the fibril are arranged parallel to one another with the same residues in
different strands stacking in-register (60-62) (Figure 1.2C).

The arrangement for how

the -sheets of a fibril pack with respect to one another has been difficult to determine
and only recently have experiments been implemented that are capable of providing
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distance constraints within a strand. From these distance measurements the first models
have been created that provide structural insights into how the -sheets pack within
fibrils (63).

Figure 1.2: Structure of tau fibrils. (A) Stacked -sheets of tau strands are arranged
perpendicular to the long axis of the fibril, with 4.7 Å spacing between strands. (B)
Electron microscopy image of tau aggregates reveal fibrillar morphology akin to other
amyloids. (C) Strands within a -sheet are arranged parallel with side chains (yellow
circles) stacked in-register.
10

1.2.4 Tau function and properties
The primary function of tau was first elucidated when it was observed that tau
was found associated with microtubules, and furthermore that the polymerization of
tubulin into microtubules was reliant on this associated protein (64).

Later it was

revealed that tau provided a role not only for initiating formation, but also for the growth
of microtubules through elongation (65). Tau has been shown to bind and support
microtubules (66, 67), while also modulating microtubule dynamics, both accelerating
the rate of polymerization and inhibiting depolymerization (68).
In determining what region of tau is responsible for the binding of microtubules it
was demonstrated that it is actually a relatively small portion of the protein that
associates. This binding region consists of semi conserved sequence repeats of around
30 amino acids located towards the carboxyl terminus of the protein (69-71). Using
constructs composed of these microtubule binding repeats, it was shown that the repeats
alone are capable of aiding tubulin assembly into microtubules (72). Interestingly, the
core of the fibrils is located within the microtubule binding repeats (60, 62, 73), with the
remaining majority of the protein remaining unstructured and providing a peripheral
“fuzzy coat” (74, 75).
The complexity of the study of tau protein is amplified in that there are 6 isoforms
expressed in the adult human brain (76). Tau can have either 3 or 4 microtubule binding
repeats depending on alternative splicing of exon 10 in the tau gene (77) (the individual
microtubule binding repeat sequences along with the largest full tau sequence, htau40, are
depicted in Appendix A).

Towards the N-terminus of tau there exist one, two, or no

insert regions, and between the N-terminal inserts and microtubule binding repeats is a
11

proline rich region (70).

The differences in the number of N-terminal inserts and

microtubule binding repeats present within tau are the basis for the variations between the
tau 6 isoforms (Figure 1.3).

Figure 1.3: Tau isoforms. Six isoforms are produced in the adult human brain.
Variations occur in the N and C termini of the protein. Either 0, 1 or 2 N-terminal inserts
can be included (gray hatched), while differences in C-terminus arise from the inclusion
of either 3 or 4 microtubule binding repeats (shaded gray). Tau can be described based
on the number of microtubule binding repeats as either 3R or 4R tau.

Additional variations in tau also occur due to post-translational modifications
including phosphorylation, glycosylation, and proteolysis (78, 79). The phosporylation
of tau is believed to be a key event in the progression of Alzheimer’s disease.

In

diseased Alzheimer’s brain hyperphosphorylation has been shown to occur at 45 possible
sites compared to only 10 sites in normal control brains (80, 81). Additionally, tau is
12

found phosporylated in disease brain 3-4 times the extent than tau in normal brain (82).
The effects of hyperphosphorylation are not fully understood, but have been shown to
cause a decrease in microtubule affinity and a reduced capacity to promote microtubule
assembly (83, 84). It has been suggested that when tau is detached from microtubules
due to hyperphosporylation, aggregation is more probable due to the increased tau
concentration in the cytosol, which ultimately leads to the formation of fibrils found in
disease.

This hypothesis is supported by experiments that have shown that

hyperphosphorylated tau extracted from Alzheimer’s disease brain is capable of
aggregating at low concentrations within a short time-period (85).

Also,

hyperphosporylation of tau has been found to occur prior to the earliest detection of any
tau aggregation in disease (86). Despite this evidence it has not been substantiated
whether phosphorylation is necessary for tau aggregation in disease.

Additionally,

hyperphosphorylation of tau has even been shown to inhibit aggregation of tau,
suggesting a protective role from aggregation (87). Contrary to the proposed opinion that
hyperphosporylation leads to the fibrillization observed in disease, evidence has been
shown by recombinant protein that phosporylation is not a prerequisite for tau
aggregation (88, 89). While the phosporylation of tau is a hallmark of Alzheimer’s
disease, the hyperphosphorylation events that have been linked to Alzheimer’s also have
been shown to occur during normal embryonic development, suggesting that by itself
phosphorylation does not result in aggregation and disease progression (90).
1.2.5 In vitro tau fibrils and polyanionic cofactors
The deposition of misfolded tau into ordered fibrillar aggregates is observed in
disease, but can also be recapitulated in vitro, as recombinant tau monomer has been
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shown to assemble into fibrils (89, 91, 92). The commonality between fibrils found in
disease and those formed in vitro is reflected by comparable structural properties.
Specifically, fibrils derived from disease and fibrils formed in vitro have both been
shown to have a common cross- structure with 4.7 Å spacing between strands (58).
Also, the morphological appearance of in vitro fibrils is indistinguishable from fibrils
found in disease (93). While recombinant tau is capable of forming fibrils consistently
under relatively simple conditions, as compared to conditions within a cell, an interesting
stimulant utilized for the process to occur is the addition of negatively charged cofactors,
including the glycosaminoglycan heparin (94).

The manner by which a cofactor

facilitates the transition of monomeric tau to highly structured aggregates is not fully
understood. One general observation is that the cofactor greatly enhances the nucleation
process needed for fibril growth to occur. Speculated mechanisms describing how a
cofactor might induce aggregation include neutralizing the repulsive electrostatic
interactions within tau that inhibit aggregation (95), and binding to multiple tau
monomers to increase local concentrations that lead to aggregation (96). Interestingly,
hyperphosphorylated tau extracted from Alzheimer’s disease brain is capable of
assembling into fibrillar aggregates without the addition of a polyanionic cofactor (85).
One explanation for the effect observed from the hyperphosphorylation of tau is that the
negative phosphates introduced neutralize the basic side-chains within the microtubule
binding region and stimulate aggregation (84).
Polyanionic cofactors bind to tau monomer (97-99) and cofactors can induce
secondary structure formation (98) in a normally unstructured monomer. With this in
mind, it is possible that the cofactor binding to the monomer allows the monomer to
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adopt a conformation that is more amenable to nucleation and growth of fibrils.
Considerations beyond the effects on nucleation, is whether the cofactor has any role in
the growth or sustainability of the fibril once nucleation has occurred. How the cofactor
interacts with the mature fibrils has been difficult to determine, and reports are
conflicting on whether the cofactor binds and is therefore included within the fibril (98,
100-102).

Questions like these are important for providing a more comprehensive

understanding of tau fibrils, as the role of the cofactor could have significant influences
on how these fibrils propagate, as well as modulate the conformations of fibrils produced.
When considering the possible roles a cofactor may have on tau fibrils, it is
important to recognize the various types of molecules shown to be capable of facilitating
aggregation.

Sulfated glycosaminoglycans such as heparin (Figure 1.4A), heparan

sulfate, and dextran sulfate have been shown to induce fibril formation in vitro (92, 103).
Importantly, observations that uncharged glycosaminoglycans do not stimulate fibril
formation, and that increases in glycosaminoglycans sulfonation results in increases in
fibril formation indicate that the ability of a cofactor to aid in fibril aggregation is
dependent on the negative charges of the molecules (103). Incubating tau with other
biological polymers such as nucleic acids (104) and polyglutamate (Figure 1.4B) (105)
has also been shown to lead to the formation of fibrils. As these polymers contain
negatively charged functional groups that are not sulfates (i.e phosphodiesters and
carboxylates), the requirements for polymers that could act as cofactors for fibril
formation would be expected to be less discriminating and simply require the presence of
multiple negative charges.

Furthermore, functional cofactors are not limited to

negatively charged polymers, as arachidonic acid, phosphatidylserine, and alkyl sulfate
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and sulfonate detergents, also induce tau aggregation (106, 107). Interestingly, in these
cases the facilitation of aggregation appears to proceed through the formation of micelles
and liposomes (107).
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Figure 1.4: Heparin and polyglutamate cofactors. (A) Heparin sulfate derived from
porcine intestinal mucosa consists of a major disaccharide unit that is homogenously
sulfonated and a minor unit that is heterogeneously sulfonated (108). (B) Polyglutamate
peptide with varying lengths of glutamate units.
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1.3 Description of research
In the work described here, the misfolding of tau monomer into fibrils was
investigated.

Previously, our group had shown that fibrils can form that are

compositionally distinct based upon the number of microtubule binding repeats present in
tau. Fibrils composed of 4R tau, 3R tau, or mixed 3R/4R tau all have been shown to have
a parallel, in-register arrangement of their -strands (62). However, whether fibrils are
conformationally distinct according to composition was unknown. In these studies we
have compared the seeded growth of both 3R and 4R tau upon addition of the different
fibril types and observed variations in seeding properties that can be attributed to
differences in conformation. In order to assess the seeding properties, we developed an
intrinsic assay that utilizes the fluorophore acrylodan as a reporter. From this developed
assay we were able to specifically observe the recruitment of tau monomer when fibril
seeds were added.
The assembly of fibrils is dependent on the addition of a polyanionic cofactor to
aid in the initial nucleation event. Using a diverse set of polyanionic cofactors including
nucleic acids and polyglutamate we induced fibril formation and characterized the
resulting fibrils by EPR spectroscopy as well as by their seeding properties. Furthermore,
the effect of a cofactor beyond the nucleation events was investigated, revealing that
cofactors are not only needed for the initiation of nucleation events, but also facilitate the
growth, as determined from seeding experiments. When studying the fibril-cofactor
interaction we found that the cofactor is incorporated with the fibrils, but can be
exchanged when another cofactor is introduced.
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In the prion field the the amplification of undetectable quantities of prion
amyloids is accomplished using a protein misfolding cyclic amplification (PMCA)
method (109). As described herein we have applied this amplification method for the
first time to tau fibrils. With our applied method we have demonstrated that fibrils
diluted several orders of magnitude can be amplified through seeded assembly to levels
that are then detectable. This method is expected to be used for the amplification and
study of fibrils derived from diseased brain, and could eventually be applied for
diagnostic purposes.
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Chapter 2: Methods
2.1 Tau constructs
Htau40 and htau23 were cloned in pET-28b plasmids (62). Natural cysteines (in
the second and third repeats), two in htau40 and one in htau23, were replaced with
serines

using

site-directed

mutagenesis

with

the

QuikChange

method

from

Stratagene/Agilent Technologies. The tau constructs with the natural cysteines replaced
are described as “cysteineless” tau.

In order to generate constructs containing the

microtubule binding repeat regions and excluding the N and C termini, fragments of K18
and K19 (110) were created and cloned into pET-28b plasmids at XhoI and NcoI sites.
The introduction of unnatural cysteines to which labels could be attached was
accomplished using site-directed mutagenesis. All sequences were verified by DNA
sequencing.
2.2 Transformation of tau DNA
Approximately 1 µg of tau DNA (gene in pET-28b plamids) was added to 20 µl
BL21-DE3 bacterial cells (Agilent) in 14 ml polypropylene tubes (BD Biosciences cat. #
352059) and incubated at 4 °C for 30 minutes. Tubes were then submerged in a 42 °C
bath for 50 seconds and immediately placed on ice for 2 minutes. 800 µl of NZY+ (10
g/L NZ-amine, 12.5 mM MgCl2, 12.5 mM MgSO4, 20 mM glucose) was added to
sample. Bacteria was then placed in a shaking incubator at 37 °C for 40 minutes and
plated on an agar plate.
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2.3 Expression and purification of tau
Tau was expressed in BL21(DE3) competent cells (Agilent). Overnight cultures
were prepared by adding a bacterial colony or applying bacteria from a glycerol stock to
LB Miller solution and allowing bacteria to grow for 15 hr at 37 °C. Bacteria from
overnight cultures (15ml) was added to 1.5 Liters of LB miller (Difco) and cells were
grown at 37 °C until the OD600 reached 0.8-1.0, after which isopropyl -D-1thiogalactopyranoside was added for a final concentration of 1 mM. Cells were further
incubated for 3 ½ hours and pelleted at 3,000 g for 15 minutes. Bacterial pellets were
resuspended in 500 mM NaCl, 20 mM piperazine-N,N’-bis(2-ethanesulfonic acid)
(PIPES), 5 mM ethylenediaminetetraacetic acid (EDTA), 50 mM 2-mercaptoethanol, pH
6.5 buffer and stored at -80 °C until later purification. Samples were heated to 80 °C for
20 minutes, cooled for 5 minutes at 4 °C, lysed by sonication, and centrifuged at 15,000 g
for 30 minutes. To the supernatants, a 55% w/v addition of ammonium sulfate was
added. Samples were allowed to incubate for 1 hour with gentle rocking, after which
samples were centrifuged at 15000 g for 10 minutes. Pellets were taken up in dH2O with
4 mM dithiothreitol (DTT), sonicated for 40 seconds, syringe filtered, and applied to a
Mono S 10/100 GL cation exchange column (GE Healthcare) in 50 mM NaCl, 20 mM
PIPES, 500 nM EDTA, pH 6.5 buffer. Tau was eluted with a 50 mM-1 M NaCl gradient
and fractions were analyzed by SDS PAGE. Enriched fractions were further purified
with a Superdex 200 size exclusion column in buffered solution (100 mM NaCl, 20 mM
2-Amino-2-hydroxymethyl-propane-1,3-diol (Tris), 500 nM EDTA, pH 7.4). Purified tau
was pooled and precipitated overnight at 4°C with an added 4-fold volumetric excess of
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acetone for constructs K18 and K19 or a 1-fold volumetric addition of methanol for
constructs htau23 and htau40, with 5 mM DTT. Precipitated tau was sedimented at
11,000 g for 20 minutes, washed in acetone (K18 and K19) with 2 mM DTT or methanol
(htau23 and htau40) with2 mM DTT and stored at -80°C.
2.4 Acrylodan labeling of tau
Precipitated tau (approximately 5 mg) was dissolved in 8 M guanidine
hydrochloride. Acrylodan (Invitrogen) was conjugated to a single introduced cysteine
(Figure 2.1) by adding dye in a 10 fold molar excess and incubating in the dark for 1 hr.
Unbound acryrodan and guanidine hydrochloride was removed by passing sample
through a PD-10 desalting column (GE Healthcare) with 100 mM NaCl, 10 mM (4-(2hydroxyethyl)-1-piperazineethanesulfonic acid, sodium salt (HEPES), pH 7.4 buffer.
Non-labeled, cysteineless tau was treated identically, with the exception that no
acrylodan label was added. Protein concentration of eluted tau was determined by the
BCA method (Pierce).

Acrylodan
Figure 2.1: Acrylodan labeling of tau. Mutated cysteine 310 (unless otherwise stated)
of tau was conjugated to fluorophore acrylodan.
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2.5 Fibril seed preparation
Fibrils were prepared by incubating 25 µM K18 or K19 (or mixture of 12.5 µM
K18 and 12.5 µM K19 in the case of mixed fibrils) for 3 days under stirring conditions
with the presence of 50 µM heparin (average molecular mass of 5,000 Da, Celsus,
Cincinnati, OH). Fibrils were cooled on ice for 15 minutes and 500 µL was sonicated
with a microtip for 20 seconds using a Fisher Scientific Sonifier (150 Series).
2.6 Seeded assay and fluorescence detection
Monomeric tau was present at a concentration of 10 µM for K18 and K19, and 20
µM for htau40 and htau23. Monomer consisted of molar fractions of 98% cysteineless
tau and 2% acrylodan labeled tau. Acrylodan label was conjugated to a single cysteine
positioned at amino acid 310, unless otherwise noted. All reactions were carried out in
100 mM NaCl, 10 mM HEPES, pH 7.4 buffer. Reaction kinetics were initiated with a 2fold molar addition of heparin and a 3% molar addition of fibril seeds. Temperature was
maintained at 37 °C with a solid state Pelletier element.

Fluorescence scans were

obtained using a Fluorolog 3 system (Horriba, Jobin) fluorometer, with the excitation
occurring at 360 nm and the corresponding emission obtained at 400 to 600 nm.
Excitation and emission slitwidths were set at 5 nm.
For reactions that involve multiple steps of seeding, tau monomer and seed
concentrations were provided at 25 µM and 8% per mol respectively at each step. These
concentrations were increased to enhance the rate of the reactions. Reactions were
allowed to progress for 1 hr. at 37 °C, and each reaction was sonicated to provide seeds
for the subsequent reaction. In the final seeding step of the multi-step procedure 3%
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seeds were used with monomer concentrations at 10 µM for K18 and K19 and 20 µM for
htau40 and htau23.
2.7 Sedimentation of tau fibrils
After the completion of fibril growth from the seeded reactions, protein
aggregates were sedimented for 40 min at > 100,000 g. The pellets were taken up in equal
volumes of gel loading buffer and applied onto a 15% SDS-PAGE gel. Proteins were
stained with Coomassie Blue and quantified by densitometry.
2.8 Thioflavin T Seeding Assay
Fibril formation was monitored by the change in ThT fluorescence (3) upon ThT
binding to tau fibrils. Reactions were carried out in a HEPES buffer (100 mM NaCl, 10
mM HEPES, pH 7.4) at 37°C, with 5 μM ThT. Tau (10μM K18 or K19) was preincubated for 5 min at 37°C, whereupon reactions were initiated with 3 mol % of
respective seeds. All reactions contained 2-fold molar excess of heparin (average MW =
5000) to monomeric tau. Fluorescence was measured using a Fluorolog 3
spectrofluorometer (Horiba Jobin Yvon), with the excitation wavelength set at 440 nm
and the emission wavelength set at 480 nm. The excitation and emission slit widths were
5 nm.
2.9 Recruitment of K19 monomer with ∆K280 K18 seeds
Fibril seeds were formed combining 25 µM tau monomer with 50 µM heparin in
buffer (100 mM NaCl, 10mM HEPES, pH 7.4), and allowing reaction to incubate at 25
°C under stirring conditions for 3 days. Fibrils were fragmented by sonicating 500 µL of
sample for 20 seconds with a microtip sonicator. For sedimentation experiments a 10%
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molar addition of K18 WT or ∆K280 K18 seeds was added to 10 µM K19 WT monomer
in buffer with 20 µM heparin, and incubated for 3 hours at 37 °C. Samples were
centrifuged at > 100,000 g for 30 minutes at 10 °C. Pellets were resuspended with 40 µL
1X SDS PAGE sample buffer and aggregated tau was assessed by SDS PAGE.
2.10 Electron microscopy
250-mesh carbon coated copper grids were placed on 10 µL drops of the
incubated sample for 40 s, 30 s on 10 µL 2% uranyl acetate, and air-dried on filter paper.
Samples were imaged with a Philips/FEI Tecnai-12 electron transmission microscope
equipped with a Gatan CCD camera.
2.11 Spin-labeling of tau monomer
Purified mutants of K18 and K19 tau containing single cysteines were labeled as
shown in (Figure 2.2).
guanidine hydrochloride.

Precipitated tau pellets were dissolved in 200-400 µL of 8 M
An approximate 10-fold molar excess of [1-oxy-2,2,5,5-

tetramethyl-pyrroline-3-methyl]methanethiosulfonate

(MTSL)

spin

label

(Toronto

Research Chemicals, Downsview, Canada) was added to tau and allowed to incubate for
at least 1 hr. Tau samples were then purified with a PD-10 column (GE Healthcare) to
remove denaturant and unreacted spin label. Concentrations of tau monomers were
determined using the BCA method (Thermo Scientific).
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MTSL
Figure 2.2: Spin-Labeling of tau. A single cysteine covalently labeled with MTSL
spin-label.

2.12 Fibril formation and EPR measurement
Spin-labeled tau was incubated with respective cofactor at room temperature for 3
days under stirring conditions. Fibrils were formed in buffered solution (100 mM NaCl,
10 mM HEPES, pH 7.4) with poly(A) RNA (Sigma P9403) at 70 µg/ml and 35 µM tau.
Poly(A) RNA size distribution was determined by agarose gel electrophoresis to be 0.22.0 kb. Additional reactions were carried out with poly(U) (Sigma P9528), double
stranded poly(AU) (Sigma P1537), transfer RNA (Sigma R8759), and RNA from baker’s
yeast (Sigma R650) with concentration ranges of 140-200 µg/ml RNA and 35-50 µM tau.
Fibrils were centrifuged at > 100,000 g for 30 min., washed with buffer, and centrifuged
for 10 minutes at > 100,000 g. Sedimented fibrils were transferred into capillary tubes
with a 0.60 mm inner diameter x 0.84 mm outer diameter (VitroCom CV6084-100).
Samples were measured with a Bruker EMX spectrometer equipped with an ER 4119HS
resonator. Spectra were obtained with a scan width of 150 G and a microwave power of
12 mW, and normalized according to total number of spins as compared with a double
integration.

The EPR signal for residual spin-labeled tau monomer, < 0.5%, was

subtracted from all spectra.
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2.13 Size distribution of RNA
The size distribution of poly(A) RNA was determined using agarose gel
electrophoresis. A 1% w/v agarose gel was cast containing 1 µg/ml of ethidium bromide
and 600 µg of RNA was loaded. The size range of the RNA was determined using a
RiboRuler High Range RNA Ladder (Thermo).
2.14 Kinetics of seeded reactions using RNA polyA
Seeded aggregation kinetics were monitored as previously described using the
intrinsic acrylodan based assay. Fibrils were formed for seeded reactions by combining
25 µM tau (K18 or K19) and 50 µg/ml of poly(A) RNA (Sigma P9403) in buffered
solution (100 mM NaCl, 10 mM HEPES, pH 7.4) and allowing reactions to proceed for 3
days under stirring conditions.

Reactions were chilled on ice for 15 minutes and

sonicated for 20 seconds to induce breakage of fibrils. Fragmented fibrils were used as
“seeds” to initiate aggregation of monomeric tau. Total monomer concentrations for K18
and K19 were 10 µM, with 98% of monomer containing cysteineless tau (cysteines
replaced with serines) and 2% acrylodan labeled tau (acrylodan covalently linked to a
cysteine at amino acid 310). Reaction kinetics were initiated with the addition of 20
µg/ml poly(A) RNA and a 10 % (seed to monomer) molar addition of fibril seeds.
Kinetics were measured at 37 °C using a Fluorolog 3 fluorometer (Horriba, Jobin). The
excitation wavelength was 360 nm and the emission spectra were scanned from 400-600
nm with a 5 nm excitation and emission slitwidth.
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2.15 Successive seeding reactions
Multistep seeding reactions were designed with and without the addition of
poly(A) RNA as a cofactor. Initial reactions were prepared combining 25 µM K18 WT
or K19 WT, 125 µg/ml RNA, and a 10% molar addition of fibril seeds. Seeded reactions
proceeded overnight, whereupon 500 µL was removed, sonicated on ice and used for the
seeding of the subsequent reaction. Each additional reaction (25 µM tau monomer) was
seeded with a 10% molar addition of seeds and was incubated overnight with and without
the addition of 125 µg/ml RNA. Fibrils for each reaction were sedimented at >100,000 g
for 30 min., pellets were washed with buffer (100 mM NaCl, 10 mM HEPES, pH 7.4)
and centrifuged for an additional 10 min. Pellets were taken up in sample buffer and
analyzed by SDS PAGE.
2.16 RNA binding to tau and exchange with heparin
Tau fibrils of either K18 WT or K19 WT were formed with the addition of 25 µM
monomeric tau, 50 µg/ml poly(A) RNA, and 10% (molar) fibril seeds in buffer (100 mM
NaCl, 10 mM HEPES, pH 7.4). Seeded reactions were inverted 3 times and incubated
for 2hr at 37 °C. Resulting fibrils were sedimented for 30 min. at >100,000 g. Pellets
were dissolved in 60µL 2% w/v SDS and the total volume was brought up to 1250 µL
with buffer. To supernatant samples 2% SDS was added and total volume brought to
1250 µL with buffer. RNA contained in pellets and supernatants was determined using a
Cary 100 Bio UV-Visible spectrophotometer.
For heparin exchange experiments fibrils were formed as above mentioned and
heparin (average molecular weight 5000, Celsus, Cincinnati, OH) was added for a final
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concentration of 50 µM. Samples were inverted 5 times and incubated further overnight
at 37 °C. Fibrils were sedimented, resuspended, and analyzed by UV-Vis as before.
Minor absorbance due to tau protein was subtracted from all spectra.
2.17 Fluorescent heparin binds to fibrils
Fibrils of K18 and K19 were prepared by adding a 10% (molar) of respective
seeds to 10 µM monomer and 50 µg/ml RNA poly(A) in 100 mM NaCl, 10 mM HEPES,
pH 7.4 buffer. Reactions proceeded for 2 hr at 37 °C. Fluorescent heparin (Invitrogen
H7482) was dissolved in PCR certified H2O (Teknova W3340) and centrifuged at >
100,000 g for 10 min and any insoluble material removed. Fluorescent heparin (average
molecular weight 18,000) was added to fibrils for a final concentration of 15 µM.
Samples were inverted 5 times and incubated overnight at 37 °C.

Samples were

sedimented at 100,000 g for 30 minutes and the supernatants removed from fibril pellets.
Pellets were dissolved with 60 µL 2% SDS. A corresponding concentration of SDS was
provided for supernatant samples. Both pellets and supernatants were brought up to the
same volume with reaction buffer and samples were analyzed by UV-vis spectroscopy.
Absorbance of fluorescent heparin was determined in both pellet and supernatant at 490
nm. RNA present was determined by absorbance at 260 nm with minor contributions
from fluorescent heparin being subtracted.
2.18 Heparin binding to fibrils by anisotropy
Binding of fluorescein-conjugated heparin (average molecular weight 18,000,
Invitrogen H7482) was monitored using a Fluorlog 3 fluorometer (Horriba, Jobin) with
an excitation wavelength of 480 nm and a measured emission of 516 nm. Integration
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times were set to 0.1 sec. and the excitation and emission slitwidths were set to 4 nm and
8 nm, respectively. Fluorescent heparin alone was measured for 5 min in buffered
solution (100 mM NaCl, 10 mM HEPES, pH 7.4). Tau fibrils (25µM tau, 50 µg/ml
poly(A) RNA) were formed as aforementioned and added to heparin for final
concentrations of 6 µM tau fibrils (total tau) and 250 nM heparin.
2.19 Aggregation of tau fibrils at high temperature and subsequent cooling
Aggregation reactions were carried out in HEPES buffer (10 mM HEPES, pH 7.4,
0.1 M NaCl or 2.0 M NaCl). Total tau monomer concentrations were 10 μM, with a
molar ratio of 98% cysteine-free (cysteines replaced with serines) and 2% acrylodanlabeled tau (position 310 replaced with cysteine and labeled). Heparin (Celsus,
Cincinnati, OH) when present was 20 μM. Stirring was utilized in all reactions to
promote aggregation. The progression of fibrillization was monitored using a Fluorolog 3
fluorometer (Horriba, Jobin). All reactions were allowed to proceed for 80 min at 343 K.
Temperature was adjusted using a solid state Pelletier element. Upon cooling from 343 K
to 275 K, samples were allowed to equilibrate and were then measured. Excitation of
samples occurred at 360 nm with a 5 nm excitation and emission slit width.
2.20 Inhibition of heparin-mediated fibril growth by high salt
Tau fibrils were prepared by incubating 25 μM K18 or K19 with 50 μM heparin
(10 mM HEPES, pH 7.4) for 3 days at 25 °C under stirring conditions. Fibrils were
chilled on ice for 10 min and sonicated for 20 seconds to induce breakage. Monomeric
K18 and K19 (10 μM; 98% cysteine free tau and 2% acrylodan labeled at position 310)
were seeded with a 3% molar addition of sonicated fibrils composed of their respective
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construct. Reaction conditions were maintained at 10 mM HEPES, pH 7.4 in the presence
of low (0.1 M NaCl) or high (1 M NaCl) salt. Heparin was added in all reactions at 20
μM. Assembly of tau monomers on fibril seeds was monitored by observing the shift in
fluorescence maximum of acrylodan label. Excitation of label occurred at 360 nm with 5
nm excitation and emission slit widths.
2.21 PMCA of tau fibrils
All reactions were carried out in Nunclon (237105) 96-well plates (Thermo
Scientific) and covered with BioDot Microplate sealing tape (dot scientific #T393).
Reactions containing tau monomer were carried out with 10 µM htau40 WT
(cysteineless), 40 µM of heparin (Celsus, average MW = 5000), and 5 µM thioflavin T
(Sigma T3516) in buffer (100 mM NaCl, 10 mM HEPES, pH 7.4). Fibril seeds were
prepared by incubating 1.4 ml of 25 µM K18 WT (or K19 WT) for 3 days or htau40 WT
for 6 days in buffer with the presence of 50 µM heparin under stirring conditions at room
temperature.

For seed dilution experiments, seeds were diluted in buffer with the

presence of 40 µM heparin. Fibril seeds (not inititally sonicated) were added to reactions
prior to incubation or PMCA sequence and are present according to the molar percentage
of seed per monomeric tau. After reactions were covered with sealant tape, plates were
covered with respective cover, and secured with sealed transfer pippetes to prevent plates
from sinking in sonicator bath (see Appendix C). Plates were placed in a water filled
microplate horn (Q Sonica #431MPX), coupled to an ultrasonic processor (Q Sonica
Q700). Temperature of bath was regulated at 37 °C with a recirculating chiller (Q Sonica
#4900). PMCA was programmed to undergo cycles of PMCA with 5 second pulses at
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5% amplitude, followed by 30 minutes of incubation at 37 °C (for one cycle). After
completion of PMCA cycles, plates were centrifuged at 1,650 g for 2 minutes at room
temperature to remove liquid accumulated on cover.

Samples were analyzed by

fluorescence using a Tecan Infinite M1000 microplate reader. Spectra of samples were
obtained using a 440 nm excitation wavelength and scanning the emission from 450 nm –
530 nm with 5 nm excitation and emission bandwidths. Quantification of tau aggregation
was determined by thioflavin T emission at 480 nm. For sedimentation experiments
same samples were pooled and 1.3 ml was centrifuged for 30 minutes at > 100,000 g at
10 °C. Pellets were washed with 1 ml of buffer and dissolved in 75 µL of 1X SDS PAGE
sample buffer and run on SDS PAGE.

32

Chapter 3: Seeding properties of 3R and 4R tau
3.1 Development of fluorescence assay to monitor 3R and 4R tau seeding
As there are 6 different isoforms of tau present—which include either 3 or 4
microtubule binding repeats—the composition of tau fibrils with respect to isoform can
vary.

Previously, our group studied tau fibril structure and determined that 3

compositionally distinct fibrils can be formed, which include fibrils composed of 3R tau,
4R tau, and fibrils that have both 3R and 4R tau integrated into the same fibril (62). In
order to better understand how microtubule binding repeats could affect fibril
propagation, we wanted to devise a methodology that would allow us to monitor the
recruitment of monomeric tau as it assembles onto fibrils. To observe this monomer
recruitment we formed fibrils of tau using heparin and applied ultrasonic perturbation to
shear the fibrils into smaller fragments that could then be used to seed the aggregation of
monomeric tau. Constructs K18 and K19 were used that contained the region responsible
for forming the core of the fibril and included either 4 or 3 microtubule binding repeats,
respectively, while omitting the C and N termini (Figure 3.1).

The ability of these

constructs to form fibrils had previously been demonstrated (96).

To monitor the

recruitment of monomer onto seeds we developed a fluorescent-based assay that utilizes
the environment sensitive dye acrylodan (111). Acrylodan was cross-linked to a cysteine
introduced at amino acid 310 in the third repeat. As the third microtubule binding repeat
is within the core of the fibrils (60, 62) it was expected that the acrylodan reporter at this
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position would be buried in the hydrophobic region of the fibril which would result in a
blue-shift in the fluorescence emission. In all reactions acrylodan labeled tau was mixed
with unlabeled cysteineless tau in a 1:50 molar ratio. Sonicated fibril seeds (Figures
3.2A,B) were added to monomer, and recruitment of monomer was monitored by
observing the acrylodan fluorescence maximum. Before the introduction of seeds, the
fluorescence of the acrylodan attached to monomeric tau (both K18 and K19) was
observed to have a maximum of 523 nm, indicative of a site that is exposed to a polar
environment (112). This accessibility to the surrounding aqueous environment is not
surprising as tau monomer has been shown to be intrinsically disordered (6, 7). Upon a
3% molar addition of K19 seeds to K19 monomer, the acrylodan emission was drastically
blue-shifted over time, demonstrating the aggregation of the monomer (Figure 3.2C).
The shift in the reciprocal of the max was plotted as a function of time and revealed the
elongation kinetics of K19 fibrils (Figure 3.2D). Likewise, K18 seeds added to K18
monomer produced a similar shift in emission that indicated the aggregation of the
monomer (Figure 3.2E,F). Importantly, without the addition of seeds no change in
emission was observed. This is expected as tau aggregation is characterized by a lagphase that reflects the time needed for nucleation to occur (46). The concentration of
seed used was shown to modulate the seeding efficiency for both K18 and K19 seeding
reactions, as increasing the seed concentration from 2% to 8% resulted in accelerated
seeding kinetics (Figure 3.3A,B).

These combined results demonstrate the recruitment

of monomer by fibrils composed of the same protein.
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Furthermore, we have

demonstrated that our acrylodan assay is capable of monitoring the aggregation of
monomer as it is recruited onto fibrils composed of the same protein.
In collaboration with Dr. Ayisha Siddiqua, tau seeding experiments were
conducted and irrespective of researcher, identical seeding properties for 3R and 4R tau
recruitment were determined (as will be discussed), indicating the robust nature in how
these fibrils propagate according to variations in the microtubule binding repeat region.

Figure 3.1: Truncated constructs K18 and K19. Constructs K18 and K19 are derived
from the microtubule binding repeat region of full-length tau. 4R tau is represented by
construct K18 and 3R tau by construct K19.
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Figure 3.2: Intrinsic tau seeding assay. Electron microscopy images of fibrils of K19
(A) and K19 (B) that were sheared by ultrasonication and used as seeds onto which tau
monomer was grown. (C) Addition of 3% K19 seeds to a mixture of monomers of 98%
K19 and 2% K19_310A1 (total concentration: 10 μM) results in a shift in the emission
maximum from 523 nm to 465 nm. Excitation: 360 nm, Emission: 400 nm – 600 nm. (D)
The inverse wavelength of the emission maximum plotted as a function of time reveals
the progression of K19-seeded aggregation. In the absence of seeds no aggregation is
observed. (E) When K18 seeds (3%) are added to a mixture of K18 monomers (98%
K18, 2% K18_310A1) a similar spectral shift as for K19-seeded reactions is observed.
(F) The inverse wavelength plotted as a function of time reveals the progression of K18seeded aggregation. In the absence of seeds no changes are observed. Values represent
mean ± s.d. (n = 3 experiments).
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Figure 3.3: Effects of altering seed concentrations. Seed concentration of (A) K18 added
to K18 monomer and (B) K19 seeds added to K19 monomer were varied. The kinetics of
the monomer recruitment was monitored for each seed concentration used.
3.2 Cross-seeding of 3R and 4R tau
Tau constructs K18 and K19 differ by the presence or absence of the second
microtubule binding repeat (Figure 3.1). In order to determine whether this variation in
sequence would affect the conformation of fibrils, as determined by seeding properties,
we carried out cross-seeding experiments that assessed the capability of 3R to grow on
4R fibril seeds and 4R to grow on 3R fibril seeds.

Reactions were performed as

previously described by introducing a 50 molar excess of monomeric unlabeled cysteinefree tau to acrylodan labeled tau and adding the respective fibril seeds. While K18
monomers were capable of elongating onto K18 fibrils, K19 monomers were not (Figure
3.4A). The aggregation of self-seeding K18 fibrils was assessed by electron microscopy
(EM), which confirmed the growth of long fibrillar aggregates (Figure 3.4B) that were
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distinguishable from the short K18 fibril seeds (Figure 3.2B). EM images taken from
attempts to grow K19 on K18 fibrils did not reveal any fibrils (Figure 3.4C), concurring
with

the

kinetic

data

that

K19

does

not

grow

on

K18

seeds.

As K18 was not capable of seeding K19, we anticipated that likewise, K19 fibrils would
be unable to cross-seed K18 monomer. Surprisingly, K19 seeds introduced to K18
monomer resulted in the aggregation of monomer (Figure 3.4D). Notably, the growth of
K19 monomer onto K19 seeds was more efficient than K18 on K19 seeds.
aggregation of both K18 and K19 monomer was confirmed by EM (Figure 3.4E,F).
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The

Figure 3.4: Asymmetric barrier for K18 and K19 cross-seeding. (A) Aggregation of
K18 monomers (98% K18, 2% K18_310A1) and K19 monomers (98% K19, 2%
K19_310A1) in the presence of 3% K18 seeds. (B) Electron micrograph of K18 fibrils
seeded with K18. (C) Electron micrograph of K19 grown onto K18 seeds. (D)
Aggregation of K19 monomers (98% K19, 2% K19_310A1) and K18 monomers (98%
K18, 2% K18_310A1) in the presence of 3% K19 seeds. (E) Electron micrograph of K18
grown onto K19 seeds. (F) Electron micrograph of K19 grown onto K19 seeds. Protein
concentrations were 10 μM. All values represent mean ( s.d. (n = 3 experiments).

By cross-seeding K18 and K19 we observed a barrier that prevents 3R tau from
growing onto 4R tau fibrils. To further test this barrier we added K18 seeds to K19
monomer at concentrations 3 and 5 times those first used (Figure 3.5A). Importantly,
even at elevated seed concentrations K19 does not grow on K18. To ensure that the
inability of K19 to grow on K18 fibrils does not originate from acrylodan fluorophore
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being attached at amino acid 310, we introduced the fluorophore at positions 317 and 322
and assessed the ability of K19 to grow on K18 fibrils (Figure 3.5B). As before K19
does not grow on K18 fibrils, which indicates that the barrier observed is not a
consequence of labeling the 310 amino acid position. Thus, our acrylodan assay reveals
an asymmetry in the cross-seeding of 3R and 4R tau, which allows fibrils of 3R tau to
seed 4R tau, but prevents 4R tau fibrils from seeding 3R tau.

Figure 3.5: Asymmetric barrier for K18 and K19 cross-seeding. (A) A robust barrier
prevents growth of K19 monomers onto K18 seeds. Circles = 9% seeds, diamonds = 15%
seeds. Growth of K18 monomers onto 3% K18 seeds is shown for comparison (triangles).
In all samples acrylodan is attached to position 310. (B) K19 aggregation monitored
through acrylodan-labeled constructs K19_317A1 (circles) and K19_322A1 (squares)
indicates that regardless of which position is labeled, K19 does not grow onto K18 seeds.
Growth of K18 onto K18 seeds (triangles) is depicted for comparison. In all cases 3%
seeds are added to 10 μM monomers.

3.3 Cross-seeding analysis by sedimentation
Using our intrinsically based fluorescent assay as well as electron microscopy we
were able to observe an asymmetric barrier between 3R and 4R tau. In order to further
validate our findings and provide an additional determination of the degree of
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aggregation we employed an assay that would measure the insoluble aggregates obtained
through seeded reactions. After monomer was allowed to aggregate with the addition of
seed, reactions were given a high speed spin to sediment any resulting fibrils formed.
Pelleted fibrils were solubilized and applied on SDS PAGE gels, and the density of the
resulting bands was quantified.

The fibrils recovered from these sedimentation

experiments is in agreement with the results of the acrylodan kinetic assay.

K19

monomer was shown to be recruited by K19 fibrils, but not by K18 fibrils (Figure 3.6A).
Alternatively, K18 monomer aggregated both in the presence of K18 and K19 seeds, with
K18 seeds resulting in considerably more aggregation, consistent with acryodan kinetics
data (Figure 3.6B).

Figure 3.6: Sedimentation of K18 and K19 fibrils. (A) Sedimented fibrils of K19 were
analyzed by 15% SDS PAGE (upper panel) and quantified by densitometry (lower
panel). (B) Sedimented fibrils of K18 were analyzed by SDS PAGE (upper gel) and
quantified by densitometry (lower panel). Protein concentrations were 10 μM. All values
represent mean ± s.d. (n = 3 experiments).
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3.4 Thioflavin kinetics
The kinetics of cross-seeding 3R and 4R tau was determined using an intrinsic
fluorescent based assay.

Traditional amyloid determination assays typically utilize

extrinsic fluorescent dyes such as thioflavin T (113).

Thioflavin T unbound has

excitation and emission maxima of 350 and 438 nm, respectively. Upon binding to
amyloid fibrils the fluorescence of the dye substantially increases with a concomitant
shift in the excitation and emission to 450 and 482 nm, respectively (114).

The

mechanism responsible for the spectral shifts and increased fluorescence is not fully
understood, but appears to occur through the binding of the fluorophore, whose long axis
runs parallel to the length of the fibril (113, 115-117). The practicality of using thioflavin
T to determine amyloid abundance is well documented. When amyloids of the same
protein are assessed under the same designated conditions, the fluorescence intensity of
the binding dye is proportional to amount of amyloid available (105, 113, 114, 117). In
order to verify the kinetics demonstrating an asymmetric barrier between 3R and 4R tau,
we employed thioflavin T as an extrinsic reporter. The kinetics were similar to what was
observed using the acrylodan assay, as K18 was able to grow on both K18 and K19
seeds, but K19 only grew on K19 seeds (Figure 3.7A,B). These results further confirm
the asymmetric barrier observed in the previous experiments.

42

Figure 3.7: Thioflavin kinetics of 3R and 4R cross-seeding. (A) Seeded fibril growth
monitored with Thioflavin T (5 μM). Changes in fluorescence intensity indicate that K18
monomers grow onto K18 seeds, but that K19 monomers do not. (B) ThT fluorescence
reveals growth of K19 monomers onto K19 seeds and reduced growth of K18 monomers
onto K19 seeds. In all thiofavin experiments, 3% seeds are added to 10 μM monomers.
All values represent mean ± s.d. (n = 3 experiments).
3.5 Seeding full-length tau
All our previous seeding experiments between 3R and 4R tau used truncated
constructs K18 and K19 as monomers to be recruited. Although these constructs contain
the region that forms the core of the fibril, we wanted to determine whether there were
any differences in the seeding properties if full-length tau was recruited.

Utilizing

monomeric full-length tau of htau40 that contains all 4 microtubule binding repeats and
htau23 that only contains 3 repeats (missing the second repeat) we repeated our acrylodan
kinetic experiments. Cysteine-free full-length tau was again mixed with a 50-fold excess
to acrylodan labeled tau at position 310. Monomer was added to fibril seeds composed of
either K18 or K19 and the kinetics observed as before. When K18 seeds were added to
htau40 monomer, htau40 was efficiently recruited as evidenced by the aggregation
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kinetics. While an immediate shift in the emission maximum did occur, htau23 did not
appear to grow efficiently on K18 seeds (Figure 3.8A). The aggregation of htau40 into
fibrils was confirmed by EM (Figure 3.8B). No fibrils were observed when htau23 was
used as monomer when EM images were taken (Figure 3.8C). Next, K19 fibrils were
used to seed full-length tau monomer.

In both htau40 and htau23, monomer was

recruited (Figure 3.8D), reaffirming the asymmetric barrier between 3R and 4R tau
observed for K18 and K19. To ensure that aggregation occurred for both htau23 and
htau40 EM images were taken after the reaction and confirmed the growth of fibrils for
both types of reactions (Figure 3.8E,F).
In our kinetic experiments we demonstrate that full-length tau is capable of being
seeded by the addition of K18 or K19 fibrils and that the barriers are the same as for the
truncated versions. As in reactions where K18 and K19 were grown on fibril seeds, fulllength tau is recruited onto the fibril seeds, thus elongating the fibril. To demonstrate that
the aggregation of htau40 and htau23 does not originate due to nucleation events
occurring within the time-window monitored, we prepared reactions of full-length tau
where no seeds were added. Without the addition of seeds, full-length monomer does not
aggregate (Figure 3.9), substantiating that the growth of full-length (Figure 3.8) occurs
due to recruitment by fibril seeds and not due to nucleation.
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Figure 3.8: Templated growth of htau23 and htau40. (A) Aggregation of htau23
monomers (98% htau23, 2% htau23_310A1) in the presence of 8% K19 seeds or 8% K18
seeds. (B) Electron micrograph of K19-seeded reaction. (C) Electron micrograph of
K18-seeded reaction. (D) Aggregation of htau40 monomers (98% htau40, 2%
htau40_310A1) seeded by addition of 8% K18 seeds or 8% K19 seeds. (E) Electron
micrograph of K18-seeded reaction. (F) Electron micrograph of K19-seeded reaction. All
values represent mean ± s.d. (n = 3 experiments)
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Figure 3.9: Full-length tau monomer does not aggregate without seeds. (A)
Kinetics of htau23 without the addition of seeds. (B) Kinetics of htau40 without the
addition of seeds. All values represent mean ± s.d. (n = 3 experiments)
As observed in our acrylodan assay, the addition of K18 seeds to htau23 monomer
resulted in an immediate shift in the emission maximum (Figure 3.8A). This shift was
minor in comparison to htau40 growing on K18 seeds. However, in order to determine
whether this shift was the result of aggregation of htau23 we performed sedimentation
experiments at the end of the reaction. When htau40 was seeded with K18 a substantial
amount of insoluble fibrils were recovered (Figure 3.10A), whereas K18 seeding htau23
resulted in little or no fibrils (Figure 3.10B). Alternatively, when K19 seeded hau40 and
htau23 monomer, both full-length proteins were found to have aggregated (Figure
3.10A,B).

These basic findings are in agreement with our kinetic and electron

microscopy data that indicate an asymmetric barrier allows the cross-seeding of 3R fibrils
to recruit 4R tau, but prevents 4R fibrils from recruiting 3R tau. Therefore, it is evident
that the seeding properties remain unchanged, regardless of using full-length tau
monomer, or monomer composed of solely the microtubule binding repeats.
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Figure 3.10: Sedimentation of full-length tau fibrils. (A) Sedimented pellets were
analyzed by 12% SDS-PAGE (upper panel) and quantified by densitometry (lower
panel). (F) Sedimented pellets were analyzed by 12% SDS-PAGE (upper panel) and
quantified by densitometry (lower panel).

3.6 Seeding with coassembled fibrils of 3R and 4R tau
Previously, it was shown that 3R and 4R tau are capable of assembling into the
same fibril [45]. We formed mixed fibrils of K18 and K19 and assessed the seeding
properties. With similar kinetics both K18 and K19 were recruited (Figure 3.11A). Fibrils
were confirmed by EM at the end of the reaction (Figure 3.11B,C). These results
indicated that fibrils of mixed 3R/4R tau recruit both 3R and 4R tau monomer, and do so
with comparable kinetics.
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Figure 3.11: Seeds of K18/K19 effectively template growth of K18 and K19. (A) The
inverse wavelength plotted as a function of time reveals the progression of K19 and K18
aggregation. Values represent mean ± s.d. (n = 3 experiments). (B, C) Electron
micrographs of K18 and K19 fibrils produced through K18/K19-seeded reactions,
respectively.
3.7 Cross-seeding 4R on 3R seeds creates new type of 4R tau fibrils
Tau aggregation results in the intermolecular stacking of strands in a parallel and
in-register manner; therefore, assembly of fibrils occurs by a template-assisted
mechanism in which the assembling monomer would assume the conformation of the
fibril (60). As we have observed that 4R tau is capable of being recruited onto 3R tau
fibril seeds, the question arose as to whether the resulting elongated fibrils of 4R tau
would then be able to seed 3R tau. When growing 4R tau on 3R tau fibrils it would be
anticipated that the 4R tau monomer would adopt the conformation of the 3R tau seeds.
As such, the resulting 4R tau fibrils would be expected to now be capable of recruiting
3R tau monomer.

In order to test our hypothesis, we designed a 3 step seeding

experiment. In the first step, K18 was grown on seeds of K19. In the second step K18
(on K19 seeds) fibrils were enriched by carrying out 3 successive seeding and elongation
cycles. In the third step the enriched K18 fibrils were used to seed K19 monomers
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(Figure 3.12A). As was hypothesized, the K18 fibrils that were templated on K19 seeds
were capable of seeding K19 monomer (Figure 3.12B, top trace).

The effect of the K19

seeds that were used to seed K18 in the first step can be discounted as the concentration
of K19 seeds was drastically diluted through the enrichment steps undertaken in the
second step of the experiment. The concentration of K19 seeds was diluted by 65,000
fold to bring K19 seeds from a concentration of 2.00 x 10-6 M to 3.1 x 10-11 M. At this
concentration K19 seeds do not accelerate aggregation, and therefore the growth of K19
monomer in the final step cannot be attributed to any K19 seeds carried over during the
reaction sequence. In order to verify the aggregation of K19 monomer into fibrils, EM
images were taken at the end of the reaction (Figure 3.12C). Importantly, when the
multistep seeding procedure was carried out with K18 seeds being used initially (instead
of K19 seeds), K19 was not capable of being recruited in the final step (Figure 3.12B,
bottom trace). To ensure that the templating experiment would provide the same result
had full-length tau been used, htau23 monomer was used in the final step and shown to
be recruited (Figure 3.13A, top trace). EM was used to confirm the presence of fibrils
(Figure 3.13B). Again, when K18 seeds were used in the initial seeding step no growth
of 3R tau monomer was observed (Figure 3.13A, bottom trace). The above described
observations are important as they demonstrate that the same protein, such as K18, can
assemble into different fibril conformations. The differences in the fibrils produced is
dependent on the initial template the monomer is offered. Furthermore, our observations
indicate that the seeding properties are propagated over multiple generations of fibril
elongation.
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Figure 3.12: Tau fibril diversification. (A) Experimental design of multicycle seeding
reactions. (B) Aggregation of K19 monomers (98% K19, 2% K19_310A1) in the
presence of 3% seeds (last step in A) monitored as a change in inverse emission
wavelength over time (top trace). When instead of K19 seeds K18 seeds were present in
the initial seeding step, no aggregation occurred (bottom trace). Values represent mean ±
s.d. (n = 3 experiments). (C) Electron micrograph representing the end point of the top
trace in (B).
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Figure 3.13: Tau fibril diversification with full-length tau. A multi-cycle seeding
procedure as outlined in Fig. 4A is used with the only difference that seeds (8 mol %) in
final reaction are added to htau23 (20 μM) instead of K19. (A) Aggregation of this
reaction (98% htau23, 2% htau23_310A1) is monitored as a change in inverse emission
wavelength over time (red). When initial seeds in this five-step procedure are K18 and
not K19 fibrils, aggregation does not occur (black trace). Values represent mean ± s.d. (n
= 3 experiments). (B) Electron micrograph representing the end point of the red trace in
A.
3.8 Mutations can affect recruitment of tau monomer by fibril seeds
Our results indicate that 4R tau can assemble into at least two conformations, one
of which is capable of recruiting 3R tau. Frost et al has shown that conformational
differences in fibrils can occur due to mutations in tau. Specifically, fibrils composed of
wild-type tau are conformationally distinct from fibrils containing the disease mutant
∆K280 (47). As we have demonstrated that conformational differences in fibrils can
dictate the recruitment of monomer, we wondered whether fibrils formed from tau with
the ∆K280 mutation, which are conformationally distinct from wild-type tau fibrils,
might recruit monomer differently. To determine this we formed fibrils with ∆K280 K18
tau and assessed whether K19 monomer could be recruited. When a 10% molar addition
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of ∆K280 K18 seeds was added to K19 monomer and incubated we found that the K19
monomer was recruited by the seeds, as determined by sedimentation experiments
(Figure 3.14A). K19 monomer without the addition of seeds did not sediment, and with
the addition of K18 seeds only a marginal amount of K19 was observed in the pellet.
Importantly, the ability of K18 ∆K280 to seed K19 is not due to K18 ∆K280 fibrils
aggregating more efficiently that K18 WT, as the sedimented seeds of K18 WT and K18
∆K280 seeds were found to be of comparable density.

Triplicate analysis of

sedimentation experiments confirmed the ability of ∆K280 K18 seeds to recruit K19
monomer (Figure 3.14B). Growth of K19 on K18 ∆K280 seeds is furthermore supported
by EM images taken after a K18 ∆K280 seeded reaction, revealing an abundance of long
fibrils that can be clearly distinguished from the short and fragmented ∆K280 K18 fibril
seeds (Figure 3.14C,D). Additionally, we applied our acrylodan assay to assess whether
K19 was recruited by ∆K280 seeds. When ∆K280 K18 seeds were added to acrylodan
labeled K19 monomer, the acrylodan emission was blue-shifted by approximately 50 nm
(Figure 3.14 E), indicating a local environment of increased hydrophobicity that would
suggest aggregation had occurred. From these results we demonstrate that a single
mutation (in this case a deletion) can alter seeding properties of tau. The effects of
mutations on the recruitment of monomer are further being investigated by Virginia
Meyer.
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Figure 3.14: ∆K280 K18 fibrils recruit K19 monomer. (A) Recruitment of K19 WT
by ∆K280 K18 seeds. K19 WT (10µM) was grown on 10% seeds of ∆K280 K18 or K18
WT fibrils with 20 µM heparin. After 3 hours of incubation aggregates were sedimented,
dissolved in 2% w/v SDS (to dissociate fibrils), and analyzed by SDS PAGE and (B)
quantified according to band density of aggregated K19 monomer. Values represent the
mean ± SEM (n = 3). (C) EM image of K19 WT (10 µM) seeded with 10 % ∆K280 WT
seeds after 3 hours of incubation at 37 °C. (D) EM image of 25 µM or sonicated ∆K280
seeds. Bars = 400 nm. (E) ∆K280 K18 seeds (10%) were added to acrylodan labeled
K19 monomer (amino acid 310). Emission is shown before addition and after addition
with 2 hours incubation at 37 °C. Excitation = 360 nm.
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Chapter 4: Tau cofactors bind and sustain fibril propagation
4.1 Fibril structure determination by EPR spectroscopy
In previous experiments the structural core of tau fibrils had been elucidated by
spin-labeling single-cysteines introduced throughout the microtubule binding repeats and
measuring the labeled fibrils by EPR spectroscopy (60, 62). In these studies heparin was
utilized to initiate the aggregation of the fibrils. As a cofactor such as heparin stimulates
aggregation of tau by inducing nucleation, we hypothesized that the nucleation of tau
with different cofactors could lead to variations in fibril conformations. Previously,
Kampers et al. had shown that RNA was capable of functioning as a cofactor to induce
fibril formation (104).

We hypothesized that fibrils formed by RNA could have a

different structural core than fibrils formed by heparin. In order to compare the structure
of fibrils formed with RNA to those with heparin we carried out EPR experiments.
Tau monomer that is spin-labeled with MTSL gives a spectrum with 3 sharp lines
that is indicative of high mobility (60) and is in line with tau monomer’s disordered
structure.

The 3 lines observed are expected for an MTSL labeled sample. Hyperfine

splitting gives rise to lines that can be determined based on the equation 2nI +1, where n
= the number of equivalent nuclei and I = nuclear spin. For a radical such as MTSL,
nuclei of 14N give n = 1 and I = 1, and therefore 3 lines are observed (118).

Tau fibrils

formed with heparin, however, reveal a broad single-line spectrum, indicative of a
structured core composed of parallel, in-register -strands (60). Stacking of labels from
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different tau molecules allows spin-exchange, leading to the loss of hyperfine structure
(60, 119). Here, we formed spin-labeled tau fibrils with polyadenylic acid (poly(A))
RNA and analyzed the fibrils by continuous wave EPR.

Fibrils of K18 or K19 were

labeled at 6 different positions within the third microtubule binding repeat. As was
observed for fibrils formed with heparin, poly(A) RNA produced fibrils with single-line
spectra (Figure 4.1), indicating a parallel, in-register arrangement of -strands at the third
repeat. These findings reveal that even when using an alternative cofactor such as
poly(A), the third repeat of tau is highly structured. Next, we assessed whether the ability
to form ordered aggregates of tau was limited to RNA, or whether we could also use
DNA. Using polydeoxyadenylic acid (poly(dA)) we formed fibrils with spin-labeled tau
as before and measured the fibril samples. As was seen for RNA, all 6 sites measured
produced single-line spectra for K18 and K19 (Figure 4.2). Using poly(A) and poly(dA)
we showed that purine-based nucleic acids were capable of producing highly ordered tau
aggregates. In order to determine whether pyrimidine-based nucleic acids could also
form fibrils with a highly structured third repeat we applied polyuridylic acid (poly(U)) to
spin-labeled tau (position 310) and again observed single-line spectra for both K18 and
K19 (Figure 4.3A). Furthermore, we characterized the fibrils formed using doublestranded polyuridylic and polyadenylic acids (poly(AU)), transfer RNA extracted from
yeast (tRNA), and total RNA from yeast. All of these RNA species produced fibrils with
single-line spectra (Figure 4.3A). As we had demonstrated that a glycosaminoglycan
(heparin) and a broad class of nucleic acids effectively promoted highly ordered
aggregation of tau, we next tested whether polyglutamate (polyGlu) would also induce
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the formation of highly ordered fibrils. The application of polyglutamate had previously
been shown to promote fibril assembly (105). As was shown for heparin and nucleic
acids, polyglutamate produces fibrils from spin-labeled monomer that provided singleline spectra (Figure 4.3B). Combined, these data reveal that the parallel, in-register
structure of tau fibrils is conserved regardless of cofactor used.

150 G
Figure 4.1: Spectra of spin-labeled tau fibrils using poly(A) RNA. Polyadenylic acid
poly(A) was used to induce the aggregation of spin-labeled monomer into fibrils. Spinlabels were attached at 6 different sites (conjugated to introduced cysteines). Fibrils were
analyzed by EPR and single-line spectra were found to occur at each of the 6 positions
within the third microtubule binding repeat for fibrils composed of both K18 and K19
tau.
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150 G

Figure 4.2: DNA produce ordered fibrils. Polydeoxyadenylic acid poly(dA) was used
to induced the aggregation of spin-labeled monomer into fibrils. Spin-labels were
attached at 6 different (conjugated to introduced cysteines). Fibrils were analyzed by
EPR and single-line spectra were found to occur at each of the 6 positions within the third
microtubule binding repeat for fibrils composed of both K18 and K19 tau.
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150 G
Figure 4.3: Nucleic acids and polyglutamate produce ordered fibrils. (A)
Polyuridylic acid (poly(U)), double-stranded polyuridylic and polyadenylic acids, transfer
RNA (tRNA) and total RNA extracted from yeast and (B), polyglutamate (polyGlu)
produce fibrils that are highly ordered as indicated from single-line spectra obtained from
spin-labeled tau.
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4.2 Seeding properties of tau using RNA as a cofactor
Previously when the seeding properties of tau fibrils were studied, we had utilized
heparin as a cofactor to initiate nucleation (120).

Our findings showed that an

asymmetric barrier exists between fibrils of 3R and 4R tau (see Chapter 3), and that
conformational variability can exist in fibrils composed of the same isoform. Although,
parallel in-registry is preserved, fibrils formed in the presence of different cofactors could
have different conformations. We next wanted to test whether cofactors affect seeding
properties of tau fibrils, as differences in the seeding properties would indicate changes in
fibril conformation. Using poly(A) RNA as a cofactor we formed fibrils of K18 or K19
and assessed these fibrils’ competency to recruit K18 and K19 monomer. When using
K18 fibrils as seeds we observed the efficient recruitment of K18 monomer, but not K19
monomer (Figure 4.4A). When applying K19 fibrils to monomer, the recruitment of both
K18 and K19 monomer was observed (Figure 4.4B). However, the cross-seeding of K18
with K19 seeds was far less efficient than K19 seeding K19. From these results we see
that the asymmetric barrier between 3R and 4R tau is recapitulated when applying
nucleic acids for aggregation. Importantly, when K18 and K19 are incubated with
poly(A) RNA, but with no seeds, aggregation does not occur (Figure 4.5), indicating that
RNA alone was not responsible for tau aggregation observed in the seeding experiments.
The seeding experiments presented here indicate the robust nature of the seeding
properties of tau, as the asymmetric barrier was observed even when using an alternative
cofactor.
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Figure 4.4: Seeding properties of 4R and 3R tau using poly(A) RNA. Seeding of
K18 and K19 monomers with a 10% molar addition of (A) K18 seeds or (B) K19 seeds.
Total monomer concentrations were 10 µM (98% WT, 2% acrylodan labeled_310A1),
with 20 µg/ml of poly(A). All values represent mean ± s.d. (n = 3 experiments).
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Figure 4.5: Aggregation does not proceed without addition of seeds. Acrylodan
assay of the kinetics of K18 and K19 (10 µM) fibril formation with the addition of
poly(A) RNA, but without seeds. All values represent mean ± s.d. (n = 3 experiments).

4.3 Size distribution of poly(A) RNA
Based on our EPR measurements and seeded reactions poly(A) RNA is capable of
producing tau fibrils. What sizes of poly(A) were used to facilitate tau aggregation was
unknown. As we utilized poly(A) extensively in previous and subsequent experiments,
we wanted to characterize the size distribution present in the poly(A) sample. Poly(A)
RNA purchased from Sigma had previously been shown to contain broad length
distributions of 0.2-6.0 kb (121). To determine the size distribution of the poly(A) RNA
used for our experiments we performed agarose gel electrophoresis with ethidium
bromide staining. From the agarose gel we found that the predominant distribution of
poly(A) RNA ranged from 0.2-2.0 kb (Figure 4.6). This indicates that the poly(A) RNA
species was not a defined size, but instead was composed of a relatively broad length
range.
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Figure 4.6: Size distribution of poly(A) RNA. Poly(A) RNA size distribution was
analyzed on a 1% agarose gel, cast with ethidium bromide. For size determination a
RiboRuler High Range RNA Ladder (Thermo) was used for comparison.
4.4 Cofactors sustain growth of tau fibrils
The aggregation of tau monomer into fibrils has been shown to proceed through a
nucleation-dependant mechanism (46). From our seeding experiments we have also
shown that preformed fibrils added to monomer abolish the lag-phase attributed to
nucleation, which also supports a nucleation-dependent mechanism for fibril formation. It
was previously suggested that cofactors are only needed for the initiation of nucleation,
and are not required for the subsequent elongation of the fibril (102). If this model is
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valid then once the nucleation event is initiated by the cofactor, the presence of the
cofactor should no longer be necessary for the fibril growth through elongation. To test
whether the cofactor was needed for the propagation of the fibrils we created an
experiment where multiple seeding steps were carried out (Figure 4.7A). The sequence
of the experiment consisted of five successive seeded reactions (cycles 1-5), whereby
fibril seeds from the previous reaction were used to seed the aggregation reaction. For
our cofactor we again utilized poly(A) RNA. In one set of reaction cycles poly(A) RNA
was included (+cf), while in another set of reaction cycles poly(A) RNA was only
included in the first reaction (-cf). At the end of each reaction cycle the fibrils were
sedimented and run on an SDS PAGE gel. For reactions using either K18 or K19 the
addition of poly(A) RNA in each of the five reaction cycles resulted in the continued
propagation of fibrils (Figure 4.7B, left panel). When the poly(A) RNA was omitted
after the first reaction cycle the fibril propagation was reduced and eventually no fibrils
were found to have sedimented (Figure 4.7B, right panel).

These results clearly

demonstrate that cofactor was needed for the fibril propagation to be sustained.
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Figure 4.7: Cofactor sustains propagation of tau fibrils. (A) Multi-step reaction
sequence for the propagation of tau fibrils. Tau fibrils are propagated by the successive
seeding of fibrils from one reaction to another. In all reaction cycles tau monomer is
present (25 µM) and the fibrils from the previous reaction are used as seeds to recruit
available monomer. In one reaction sequence, (+cf), poly(A) RNA cofactor is provided
in all 5 reaction cycles, whereas in another reaction sequence, (-cf), poly(A) cofactor is
only provided in the first reaction cycle. (B) SDS PAGE gels of sedimented fibrils from
the experiment using either K18 or K19. The sedimented fibrils from each reaction cycle
are shown with poly(A) RNA in all reactions (left panel), or with poly(A) RNA only
included in the intial reaction (right panel).
In the multi-step seeding experiment we observed a strong dependence of the
propagation of the fibrils with the addition of cofactor. In previous kinetic experiments
using heparin as a cofactor (120), and the above described seeding experiments using
poly(A) RNA as a cofactor (Figure 4.4), we had always included the cofactor with
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monomer, to which seeds were added. Based on the results from the multi-step seeding
experiment (Figure 4.7), we would expect that when conducting a seeded reaction that
there would be a significant difference in the seeding efficiency depending on whether a
cofactor was included.

Using poly(A) RNA as a cofactor we carried out seeding

experiments with and without the addition of cofactor (Figure 4.8). Our kinetics data
reflected the muti-step seeding experiment, showing for both K18 and K19 that without
the addition of cofactor the fibril propagation is dramatically reduced. Furthermore, as
nucleation of fibrils was shown not to occur in the time-period observed (Figure 4.5), the
growth induced by the addition of seeds can be fully attributed to the elongation of the
fibril seeds and not due to the formation of new fibrils through nucleation.

Figure 4.8: Cofactor is needed for elongation of fibrils. Acrylodan kinetics of seeded
aggregation of K18 (A), or K19 (B) on respective seeds (10 % by mole). Reactions were
carried out with (20 µg/ml) or without the addition of poly(A) RNA. All values represent
mean ± s.d. (n = 3 experiments).
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4.5 Tau-cofactor interaction is electrostatic
By observing the effect of the cofactor on seeding efficiency we had observed a
strong dependence of fibril propagation on the presence of cofactor. It could be expected
that as the core of the fibrils contain a largely basic region, that a polyanionic cofactor
would facilitate fibril growth through electrostatic interactions with the fibril core. To
demonstrate that interactions between two species occur via electrostatics, the application
of high salt can be used (122, 123). When binding occurs through oppositely charged
surfaces the conditions of high ionic strength through the introduction of high salt is seen
to be capable of abolishing these electrostatic interactions. If the negatively charged
cofactor facilitated fibril growth through oppositely charged electrostatic interactions
with tau monomer or fibril, then it would be expected that here also elevating the ionic
strength would reduce the fibril assembly. We observed the self-seeding kinetics of K18
and K19 fibrils (K18 fibrils seeding K18 and K19 fibrils seeding K19) in the presence of
low (0.1 M NaCl) and high (0.5 or 1.0 M NaCl) salt. When using poly(A) RNA as a
cofactor low salt conditions allowed for the seeded growth of K18 and K19 fibrils,
whereas when the concentration of salt was elevated the fibril growth was abolished
(Figures 4.9A,B). To see whether the inhibitory effect of high salt was also reflected
when using a different cofactor we carried out the experiments using heparin instead. As
was observed for poly(A) RNA the introduction of high salt inhibited the fibril growth
(Figure 4.9C,D). These experiments indicate that the cofactor interacts with tau during
the elongation of the fibril and that the interactions are electrostatic.
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Figure 4.9: High salt concentrations inhibit fibril elongation. Acrylodan kinetics of
seeded-aggregation with conditions of low and high salt. (A) Growth of K18 monomer
on K18 seeds with 20 µg/ml RNA, and (B) growth of K19 monomer on K19 seeds with
20 µg/ml RNA. (C) K18 self-seeded growth with 20 µM heparin (D) K19 self-seeded
growth with 20 µM heparin. All tau concentrations were 10 µM. All values represent
mean ± s.d. (n = 3 experiments).

4.6 Cold dissociation of tau fibrils
Computational studies with our collaborators have indicated that at high
temperature (340 K) -sheet-strand probability reaches a maximum (124).

The

temperatures used for our aggregation reactions ranged from 25 °C to 37 °C. In all of our
experiments thus far we have provided cofactor for the nucleation of fibrils. Whether
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fibrils could be formed at higher temperatures conducive to -sheet-strand probability
(340 K) without the presence of a cofactor was not known. Using our acrylodan assay
we monitored the fibril formation with and without the addition of heparin at 343 K.
With the addition of heparin the aggregation was rapid, while without any cofactor the
reaction proceeded slowly (Figure 4.10A). At the end of the reactions sample was
mounted on EM grids. EM images revealed fibrils formed with and without heparin.
However, fibrils formed without heparin appeared to have disintegrated (Figure 4.10B).
We reasoned that this disintegration could have originated from the temperature change
as the fibrils cooled during the mounting procedure carried out at room temperature. To
test the temperature effects on tau fibril integrity we monitored changes in the emission
spectra. The acrylodan fluorescence blue-shifted during amyloid formation at 343K with
and without heparin (although to a lesser extent) (Figure 4.10C,D). After heating, the
K18 solution was cooled to 275 K. When heparin was added, cooling to 275 K resulted
in an additional blue-shift in the acrylodan fluorescence, which could be attributed to a
further maturation of the fibrils (Figure 4.10C). However, when K18 fibrils without
heparin were cooled to 275 K the main peak of acrylodan fluorescence red-shifted back
to the original monomeric position (Figure 4.10D). Meanwhile, the shoulder region
between 400 and 450 nm increased, possibly indicating an increase in soluble oligomers.
These experiments indicate that K18 can form fibrils without heparin at high
temperatures, and when cooled the fibrils cold dissociate. Fibrils formed with cofactor
do not cold-dissociate suggesting that the heparin provides a stabilization role in
preventing dissociation.
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Figure 4.10: Heparin locks the tau protein K18 fibril and prevents its reversion. (A)
Kinetics of fibril formation at 343 K in the presence (blue) and absence (red) of heparin,
as determined by the shift of the emission maximum of acrylodan labeled tau. Values
represent mean ± s.d. (n = 3 experiments). (B) EM images of fibrils formed at 343 K in
the presence (left panel) and absence (right panels) of heparin. Two images are shown for
fibrils formed without heparin. Bar = 200 nm. (C and D) Representative spectra of
aggregation reactions in the presence and absence of heparin, respectively. Spectra of
monomeric tau (green), after aggregation of fibrils at 343 K (blue), and when cooled to
275 K (purple). Protein concentration = 10 µM. NaCl concentration = 0.1 M. The data
indicate that heparin prevents tau fibrils from dissociating in the cold.
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4.7 Cofactor binds to fibrils
The cold dissociation experiments indicated that the introduction of a cofactor
prevents fibril dissociation when cooled. If the cofactor provides a stabilizing role it
would be likely that the cofactor binds to the fibril. To assess cofactor binding to fibrils
we utilized poly(A) RNA as a cofactor for fibril formation. After forming the fibrils with
the RNA the insoluble fibrils were sedimented and pelleted fibrils were separated from
supernatants. The pellets were dissolved in 2% w/v SDS (to dissociate fibrils) and
adjusted to the same volume as the supernatant with buffer and 2 % w/v SDS. As RNA
absorbs strongly in the UV region, we utilized UV-Vis spectroscopy to determine
whether RNA was associated with the fibrils (pellet) or whether it did not bind
(supernatant).

Absorbance contributions due to tau protein were negligible, as we

utilized truncated constructs that contained only 1 tyrosine and no tryptophan residues.
Spectra for the analysis of RNA bound to K18 revealed that a majority of the RNA was
contained in the pellet, indicating that RNA binds to tau fibrils (Figure 4.11A). The total
RNA concentration used for these reactions was also analyzed and was found to be
approximately equal to the sum of the RNA in the pellet and supernatant. Triplicates
confirmed the binding of RNA to K18 fibrils (Figure 4.11B). For K19 fibrils we also
observed that a majority of the RNA provided is bound to the fibrils (Figure 4.11C,D).
These findings indicate that the cofactor-tau interaction is not limited to monomer-tau
during nucleation, but instead the cofactor binds and is a constituent of the fibrils.
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Figure 4.11: RNA binds to tau fibrils. Tau fibrils were prepared incubating 25 µM tau
with 50 µg/ml poly(A) RNA. Sedimented samples were analyzed for poly(A) RNA
contained in the pellet and supernatant. The pellet was dissolved and fibrils dissociated
using 2% w/v SDS. Spectra for RNA contained in pellet and supernatant, and total RNA
used, for (A) K18 fibrils and (B) K19 fibrils. Absorbance of RNA for triplicate samples
for K18 (B) and K19 (D) fibrils. Values for (B) and (D) represent mean ± s.d. (n = 3
experiments).
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4.8 Cofactors can exchange on the fibril
4.8.1 Cofactor exchange by sedimentation analysis
In the case of poly(A) RNA we have shown that the cofactor binds to the fibril.
We next wanted to determine whether once bound, if a cofactor was capable of being
removed through the addition and exchange of another cofactor, or whether the cofactor
binding was more permanent. To determine this we formed fibrils with poly(A) RNA
and added an excess of heparin (50 µM) to see whether the heparin was capable of
exchanging with the RNA. When analyzed by UV-Vis we found that the heparin had
substantially removed the poly(A) RNA, as the majority of the RNA was now found in
the supernatant. The poly(A) RNA removal was observed for fibrils of either K18
(Figure 4.12A) or K19 (Figure 4.12D). We next wanted to determine whether the
removal of RNA through the addition of heparin had any effect on the integrity of the
fibril. If heparin were removing RNA, possibly through replacement, it is possible that
structural disturbances or general change in aggregate morphology would be observed.
By EM we analyzed fibrils of K18 before (Figure 4.12B) and after (Figure 4.12C) the
addition of heparin and found that the integrity of the tau aggregates was still upheld,
with no changes in the fibrillar morphology detected. The same structural adherence was
also observed for fibrils of K19 with and without the addition of heparin (Figure 4.12
E,F).
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Figure 4.12: Removal of RNA by the addition of heparin. The removal of RNA was
determined after the addition of heparin for K18 (A) and K19 (B) fibrils. Poly(A) RNA
found in the supernatant was analyzed by UV absorbance at 260 nm. All values in
represent mean ± s.d. (n = 3 experiments). EM images were taken of sample before and
after the addition of heparin. For K18 fibrils, (B), before and (C) after heparin addition.
For K19 fibrils, (E) before, and (F) after addition of heparin. Bar = 400 nm.
The addition of heparin to fibrils formed with poly(A) RNA resulted in the
dissociation of RNA from the fibrils. It could be assumed that the heparin removal
occurred via the exchange of heparin bound to the fibril. However, when heparin was
added to remove the RNA (Figure 4.12), it was not clear whether the heparin was binding
and taking the place of the RNA. To test whether heparin exchanges with RNA on the
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fibril we utilized heparin conjugated with fluorescein. When fluorescent heparin (15 µM)
was added to fibrils formed with RNA, the RNA was shown again to be removed (Figure
4.13A,B). The fluorescent heparin was also accounted for in the pellet and supernatant
samples, with the majority of the heparin found to be in the pellet (Figure 4.13C,D). For
both K18 and K19 fibrils the addition of heparin therefore resulted in the removal of the
RNA from the fibrils and the binding of the heparin.

From these sedimentation

experiments it is clear that heparin added to the fibrils exchanges with the RNA.
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Figure 4.13: Exchange of RNA for heparin. Fluorescein-conjugated heparin was
added to poly(A) RNA/tau fibrils. RNA in the pellet and supernatant after addition of
heparin was assessed by Abs 260 nm, for (A) K18 and (B) K19 fibrils. After exchange
heparin bound to fibrils was determined by heparin found in the pellet and supernatant
(Abs at 490 nm) for (C) K18 and (D) K19 fibrils. All values represent mean ± s.d. (n = 3
experiments).
4.8.2 Cofactor exchange by anisotropy analysis
To determine the binding of heparin by an alternative assay we devised a
fluorescence anisotropy experiment. The binding of heparin in solution to large fibrils
would be expected to reduce the mobility of the heparin, which could be observed as a
decrease in the rate of tumbling, resulting in an increase in the fluorescence anisotropy.
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When the heparin fluorophore is excited with vertically polarized light the anisotropy r
can be determined by measuring the intensities of the vertical (IVV) and horizontal (IVH)
emissions of the fluorophore and applying the equation

 

(1)

Polarization biases introduced by the instrument—for example due to biases in
monochromators to transmit vertical versus horizontal emissions— can be accounted for
by applying the G factor (125-127), or grating factor. The determination of the G factor
requires the excitiation of the fluorophore with horizontally polarized light and the
measurement of the resulting vertical (IHV) and horizontal (IHH) emissions. The G factor
is described as
(2)

Applying G factor to anisotropy gives

 

(3)

We measured the anisotropy of fluorescent heparin for three-hundred seconds and added
poly(A) RNA/tau fibrils and observed the change in anisotropy. Both fibrils of K18 and
K19 caused large increases in the anisotropy (Figure 4.14A,B) indicating the binding of
the heparin to the RNA fibrils. In studies focusing on the interaction between tau and
cofactors, it was shown that cofactors bind to tau monomer (97, 98). To ensure that the
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large increases in anisotropy observed when adding fibrils to heparin were not caused by
binding to tau monomers contained in the fibril mixture, we also performed experiments
where tau monomer alone was added to fluorescent heparin. Conservatively, we added
the same concentration of tau monomer that our fibrils contained. When monomer was
added to K18 fibrils an increase in the anisotropy occurred (Figure 4.14C), but was
marginal compared to adding fibrils to heparin. When adding the same concentration of
K19 monomer to the heparin the anisotropy increased (Figure 4.14D), but was
significantly less than the anisotropy change when K18 monomer was introduced.
Together our results show that cofactors are incorporated into tau fibrils.
Furthermore, the binding of a cofactor to the fibril is not a static event, as we have shown
that cofactor exchange on the fibril can occur. These findings are important as they
indicate that the cofactor is not only important for nucleation and growth, but is also a
component of the fibril.
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Figure 4.14: Heparin binds to tau fibrils as shown by fluorescence anisotropy. The
fluorescence anisotropy of fluorescein-conjugated heparin was monitored before and
after the addition of tau fibrils. (A) Addition of K18 poly(A) RNA fibrils after 300
seconds. (B) Addition of K19 poly(A) RNA fibrils after 300 seconds. In control
experiments tau monomers were added to heparin, (C) K18 and (D) K19. Final
concentrations of heparin and tau fibrils were 250 nM and 6 µM, respectively. All values
represent mean ± s.d. (n = 3 experiments).
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Chapter Five: Amplification of tau fibrils using PMCA
5.1 Seeding efficiency is dependent on seed concentration
From our seeding experiments we have shown that we can rapidly propagate tau
fibrils when providing tau monomer and cofactor for recruitment. The efficiency of
monomer recruitment is dependent on the concentration of fibril seeds introduced. When
seeding K18 and K19 monomer with respective fibrils, we observed an acceleration in
the reaction kinetics when increasing the concentration of fibril seeds (Figure 3.3). In
order to further assess the efficiency of aggregation we applied a broad set of seed
concentrations and monitored the recruitment of monomer by thioflavin T fluorescence.
Htau40 monomer was seeded with non-sonicated fibril seeds of K18 WT, with molar
seed concentrations ranging from 0.1% to 8% seed (Figure 5.1). After the addition of
seeds the reactions were sonicated for 5 seconds (in bath) and after 6 hours of incubation
the efficiency of the reactions was determined. Our data indicate that the efficiency of
aggregation drastically decreases with decreasing seed concentration. After accounting
for fluorescence intensity contributions of introduced seeds we observed that the seeding
capacity was limited at 0.1% seeds. At 0.1% seeds the aggregation of monomer was
nearly indistinguishable from samples without seeds (monomer only controls).
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Figure 5.1: Seeding of tau monomer with varying seed concentrations. Various
concentrations of K18 WTseeds were added to recruit monomeric tau. Htau40 WT
monomer (10 µM) was incubated with seeds and 5 µM thioflavin T (ThT) for 6 hr.
Fluorescence emission was measured at 480 nm, with an excitation of 440 nm. Heparin
was included in all reactions at concentrations of 40 µM, except for samples of “ThT
only” (Thioflavin T only). All values represent mean ± SEM (n = 4 experiments).

5.2 Fibril amplification concept
We have shown that small amounts of fibril seeds added to monomeric tau are
capable of recruiting the monomer into the fibril. However, when seed concentrations
are too low the seeding capacity is lost and the conversion of monomer to fibril does not
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occur within the time period-frame of the experiment. In the prion field a protein
misfolding cyclic amplification (PMCA) assay that amplifies minute concentrations of
misfolded prion amyloid has been developed (109). The basis for the assay includes the
alternation of fibril growth and breakage cycles that are applied to amplify undetectable
concentrations of fibrils. As we have also witnessed a limitation in the seeding capacity
at a lowered seed concentration (0.1%) for tau fibrils, we asked whether the principles of
PMCA could be applied to amplify tau fibrils previously undetectable. We designed an
experimental setup to amplify tau fibrils that utilizes a similar apporach as is used for
prion amplification. The sequence includes the introduction of minute concentrations of
tau fibrils as seeds to monomer, and the subsequent sonication and incubation to amplify
the fibrils. The sonication is applied to break the fibrils and create additional fibril ends,
onto which monomeric tau can grow. The prolonged incubation phase allows for the
time needed for the elongation of the fibrils to occur through the recruitment of
monomer. As a result of multiple cycles of breakage and elongation (Figure 5.2), an
initially low and undetectable fibril seed concentration can be amplified through
propagation to a fibril concentration that is then detectable.
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Figure 5.2: PMCA applied to tau fibrils. Tau fibril seeds (blue arrows) are introduced
to tau monomer. Initial fibrils are propagating by undergoing alternating cycles of
growth (incubation) and breakage (applied sonication). At the end of multiple cycles of
PMCA, an initially low concentration of fibril seeds has been amplified.
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5.3 Fibril amplification of tau fibrils
In collaboration with Virginia Meyer, the PMCA concept was applied to tau
fibrils. To test the PMCA concept on the amplification of tau fibrils we added K18 fibril
seeds (initially unsonicated) at a concentration of 0.1% to htau40 WT monomer. This
concentration was chosen because a seeded reaction after 6 hours was shown to result in
a minimal amount of monomer aggregation (Figure 5.1).

As before, we used the

thioflavin T assay for the determination of fibrillar aggregation. The seeded reactions
underwent 12 cycles of PMCA, with a 5 second sonication pulse, followed by a 30
minute incubation time, giving a total elapsed time of 6 hours. At 4 cycles, 8 cycles and
12 cycles samples were measured by fluorescence (Figure 5.3A), which showed that with
successive cycles the aggregation of monomer increased. Importantly, to rule out the
occurrence of monomer aggregation through nucleation, we included a monomer control
that contained no added seeds (monomeric tau was ensured by applying chemical
denaturant) and was carried out through the 12 cycles of PMCA. As this monomer
control did not aggregate, it is evident that the aggregation enhancement imparted by
PMCA cycles is due to the amplification of the initial fibril seed added. Additionally,
thioflavin T alone after 12 cycles of PMCA did not result in an increased fluorescence
intensity (Figure 5.3A).
To compare seeded reactions with PMCA reactions we sonicated the seeded
reaction for 5 seconds and measured the growth after 6 hours of incubation—the same
incubation time elapsed after 12 cycles of PMCA. As was expected a single pulse of
sonication was not sufficient to effectively promote the aggregation of the monomer
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(Figure 5.3B). The proposed mechanism of propagation by which PMCA amplifies a
dilute concentration of fibril seed is suggested to occur not due to the total time the
reaction undergoes sonication, but due to the periodic pulses of sonication (breakage) that
are spaced between steps incubation (growth).

To test whether the periodicity of

sonication was important for fibril amplification we applied an initial sonication pulse of
60 seconds (total sonication time for 12 cycles of PMCA) to the seeded reaction and
allowed the reaction to incubate for 6 hours. As was expected the reaction did not result
in a substantial amount of aggregation of the monomer (Figure 5.3B), in agreement with
the idea that PMCA functions to promote fibril amplification due to applied cycles of
sonication and incubation. After the reactions were completed identical samples were
pooled, sedimented and analyzed by SDS PAGE to verify the findings observed using the
thioflavin T assay. As was observed using the thioflavin T fluorescence assay, seeded
reactions undergoing 12 cycles of PMCA resulted in the aggregation of the monomer.
Control samples, to which no seeds were added, did not result in the aggregation of
monomer after 12 PMCA cycles. When applying 5 second and 60 second pulses to
seeded samples and incubating for 6 hours, there was a minimal amount of aggregated
monomer, which is consistent with the marginal fluorescence increases observed with the
thioflavin T assay. Together, the thioflavin T fluorescence assay and fibril sedimentation
experiments reveal the efficacy of applying PMCA to amplify tau fibrils.
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Figure 5.3: PMCA applied to tau fibrils. Htau40 WT (10 µM) underwent PMCA with
the addition of 0.1% K18 WT seeds with 40 µM heparin. (A) ThT fluorescence of
htau40 WT with no seeds (12 PMCA cycles) and 4, 8, and 12 PMCA cycles with the
addition of 0.1% seeds. ThT was present in all reactions at 5 µM. (B) Samples were
sonicated continuously for 5 seconds (duration of 1 sonication step of PMCA) and 60
seconds (duration of combined 12 cycles of PMCA sonication), and then incubated for 6
hours. Samples undergoing 12 cycles, with and without seed addition are shown for
comparison. (C) SDS PAGE of sedimented fibrils at the end of 12 PMCA cycles (or 6
hours). All values represent mean ± SEM (n = 8 experiments).
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5.4 Sensitivity of PMCA
We had demonstrated the efficacy for PMCA applied to tau fibrils when using
0.1% K18 fibrils as seeds and performing 12 cycles of PMCA. Next we wanted to assess
the sensitivity of PMCA to determine whether seeds further diluted could be amplified.
We seeded htau40 WT monomer with fibril seeds of K18 ranging from 0.1% to
0.00001% of monomer tau concentration and applied 40 cycles of PMCA. Interestingly,
at all the seed concentrations tested we observed amplification, with decreasing
amplification occurring with each seed dilution. Notably, the control for no seeds added
did not result in any aggregation after 40 PMCA cycles. As was expected, ThT only and
0.01% seeds (seeds only) also did not result in elevated fluorescence (Figure 5.4A).
When observing PMCA reactions substantial variability is observed between identical
samples (Figure 5.5). Emission spectra of thioflavin T indicate that the variability in
amplification can arise, sometimes deviating due to a single reaction (e.g. see reaction in
well B1). It is possible that this variability originates due to an uneven force distribution
in the bath. If PMCA were to be applied as an assay for the accurate determination of tau
fibrils, the variability would need to be accounted for when determining the number of
trials chosen. In summary, the results indicate that tau fibrils can be amplified, even
when diluted by several orders of magnitude.
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Figure 5.4: Amplifying K18 fibrils at dilute seed concentrations. Reactions
underwent 40 cycles of PMCA (or 20 hours of incubation), and aggregation efficiency
was determined by thioflavin fluorescence (thioflavin T present in reactions at 5 µM).
(A) Varying initial seed concentrations of K18 fibrils from 0.1 to 0.00001% per mole of
monomer (10 µM). Control reactions were performed with 10 µM htau40 WT monomer
and underwent 40 PMCA cycles without added seeds (no seeds). (B) Samples with
added heparin (40 µM) and no added heparin were compared for effect of cofactor. The
influence of periodic sonicating was determined by applying 5 seconds and 200 seconds
of sonication (1 cycle and 40 cycles of PMCA, respectively) and incubating samples for a
total duration equivalent to of 40 cycles of PMCA (20 hours). All values represent mean
± SEM (n = 8 experiments).
87

Previously we had demonstrated arequirment of a cofactor for fibril propagation
when carrying out seeded reactions. In all the PMCA experiments thus far the cofactor
heparin was included in the reactions. As fibril breakage and elongation are the basis for
PMCA we would expect that the omission of cofactor from the reactions would inhibit
PMCA by reducing the efficiency of the elongation phase. When comparing PMCA
reactions using the same seed concentration, but with and without added heparin (40
µM), we observed a substantial decrease in the amplification for reactions without added
heparin (Figure 5.4B).

It should be noted that when introducing the seeds a low

concentration of heparin (1.6 µM) is carried over to the reaction, which would account
for the minor amplification observed for the “no heparin reaction”. Again, we tested
whether the amplification of the fibrils was occurring in part due to the periodic
incubation cycles and not solely due to the incubation phase. When sonicating for one
cycle (5 seconds) there was only slight aggregation observed. When sonicating for the
total duration of 40 PMCA cycles (200 seconds) at the beginning of the reaction there
was no substantial aggregation observed, further indicating that PMCA occurs due to the
periodic breakage of fibrils in between incubation phases.

Our results reiterate the

dependence of fibril elongation on the presence of a cofactor and validate that the
mechanism of PMCA is based on cycles of combined breakage and growth of fibrils.
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Figure 5.5: Variability of PMCA. Variability of ThT spectra after 40 cycles of PMCA
using K18 fibrils as seeds and htau40 WT as recruited monomer. Spectra were obtained
in a 96-well plate (n = 8). A1-A8 = 0.1% K18 seeds; B1-B8 = 0.01% seeds; C1-C8 =
0.001% seeds; D1-D8 = 0.0001% seeds; E1-E8 = 0.00001% seeds; G1-G8 = no seeds;
A11-H11 = 0.01% seeds (no heparin); A12-H12 = 0.01% seeds only. Excitation = 440
nm, Emission = 450nm -530 nm.

5.5 Seeding with full-length seeds
In all of our seeding reactions thus far we used K18 fibrils (unfractured) as initial
seeds and propagated the fibrils by recruiting htau40 WT monomer.

In order to

determine whether fibrils of htau40 WT could be propagated when htau40 WT fibrils
were used as seeds we performed 40 cycles of PMCA with concentrations of 0.1% to
0.00001% htau40 WT seeds. As was seen when using K18 seeds, htau40 seeds could be
effectively propagated, even to some extent when using the lowest seed concentration
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tested (0.00001%) (Figure 5.6A).

Also, we again assessed the impact of omitting

cofactor, and found that without added heparin the reaction efficiency was significantly
reduced (Figure 5.6B). Furthermore, the importance of applying sonication periodically
to break the fibrils was again demonstrated as reactions with sonication applied only at
the beginning of the reaction did not result in effective amplification (Figure 5.6B).
These results indicate that like fibrils composed of K18 tau, htau40 fibrils are capable of
being amplified.
Next, we asked whether 3R tau could be amplified by PMCA. Using htau23 as
monomer and htau23 fibrils (unfractured) as seeds we assessed the amplification
sensitivity (Figure 5.7A). After 40 PMCA cycles we observed amplification compared to
that contained monomer but no seeds; however the seed concentration amplified was
limited to 0.001%. The addition of cofactor was again shown to enhance amplification,
as reactions with no added cofactor were amplified to a significantly lower extent (Figure
5.7B). Thus it is clear that fibrils composed of truncated tau, as well as fibrils of fulllength tau (either htau40 or htau23), are capable of being amplified.
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Figure 5.6: Amplifying htau40 fibrils. Reactions underwent 40 cycles of PMCA (or 20
hours of incubation) with 10µM htau40 WT monomer, and aggregation efficiency was
determined by thioflavin fluorescence (thioflavin T present in reactions at 5 µM). (A)
Varying initial seed concentrations of K18 fibrils from 0.1 to 0.00001% per mole of
monomer (10 µM). Control reactions with 10 µM htau40 WT monomer underwent 40
PMCA cycles without added seeds (no seeds). (B) Samples with added heparin (40 µM)
and no added heparin were compared for effect of cofactor. Influence of periodic
sonicating was determined when applying 5 seconds and 200 seconds of sonication (1
cycle and 40 cycles of PMCA, respectively) and incubating samples for total duration of
40 cycles of PMCA (20 hours). All values represent mean ± SEM (n = 8 experiments).
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Figure 5.7: Amplifying htau23 fibrils. Reactions underwent 40 cycles of PMCA (or 20
hours of incubation) with 10 µM htau23 WT monomer, and aggregation efficiency was
determined by thioflavin fluorescence (thioflavin T present in reactions at 5 µM). (A)
Varying initial seed concentrations of K19 fibrils from 0.1 to 0.00001% per mole of
monomer (10 µM). Control reactions with 10 µM htau23 WT monomer underwent 40
PMCA cycles without added seeds (no seeds). (B) Samples with added heparin (40 µM)
and no added heparin were compared for effect of cofactor. Influence of periodic
sonicating was determined when applying 5 seconds and 200 seconds of sonication (1
cycle and 40 cycles of PMCA, respectively) and incubating samples for total duration of
40 cycles of PMCA (20 hours). All values represent mean ± SEM (n = 8 experiments).
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Chapter 6: Discussion
6.1 Seeding of 3R and 4R tau
There have been three distinct types of fibrils identified based on the composition
of 3R and 4R tau (3R fibrils, 4R fibrils, and 3R/4R fibrils). Studies have revealed that the
core of these fibrils is composed of the microtubule binding repeats, and that -strands of
the fibril are all arranged parallel with their side-chains in-register (60-62). While the
core of the fibrils and the -sheet stacking are conserved within compositionally distinct
fibrils, structural variations could occur based on differences in the packing of -sheets
within the fibril.

Such variations in the -sheet packing would therefore impart

conformational differences among fibrils, and would be expected to alter biophysical
properties. The results of our seeding experiments have shown that key differences exist
between the identified fibril types, and indicate that the fibrils are conformationally
distinct. Our findings show that 3R tau fibrils, as well as mixed 3R/4R fibrils, seed both
3R and 4R tau. Fibrils of 4R tau, however, seed 4R tau, but not 3R tau indicating an
asymmetric barrier exists between 3R and 4R tau. When 4R tau was first seeded with 3R
tau fibrils, 3R tau was then capable of being seeded by 4R tau fibrils, indicating that a
new conformation of 4R tau fibrils had been produced and further instilling the idea that
fibril propagation proceeds by a templated mechanism. Based on seeding properties, we
have demonstrated the occurrence of four conformationally distinct fibrils—which
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include 3R fibrils, 3R/4R fibrils, and two conformations of 4R fibrils (one that seeds 3R
tau and one that does not)
In our seeding experiments we have utilized truncated constructs K18 and K19
that contain the microtubule binding repeat region and omit the N and C termini. These
truncated versions of tau are reflective of the protease resistant core region of fibrils
found in Alzheimer’s disease. Similar to constructs K18 and K19, this protease resistant
core of Alzheimer’s disease fibrils is composed of around 100 amino acids, and includes
most of the microtubule binding repeat region (73). Additionally, the truncation of tau
through proteolysis is observed in fibrils found in disease (128, 129) and has been linked
as a precursor towards the aggregation of tau into NFTs (130)—despite other findings
disputing this requirement (131). Furthermore, tau that has been truncated at the C and N
termini beyond the microtubule repeat region has been shown to assemble into fibrils
more quickly and efficiently than full-length tau (129), and is capable of nucleating the
aggregation of full-length tau (132). Our findings indicate that fibrils composed of
truncated constructs K18 and K19 effectively seed both truncated and full-length tau. As
the seeding properties observed were the same whether truncated or full-length constructs
were used, it would be expected that the region of the protein outside the fibril core may
not have any marked contributions to the fibril conformation. This would be in line with
the flanking regions forming an intrinsically disordered coat (74, 75).
The diversification of amyloid fibrils is well documented in prions, and is
reflected by strain variations in both mammals and yeast (133-136). The basis of distinct
prion strains is considered to originate from conformational differences between fibrils
94

(137). When monomeric protein is assembled onto the prion fibril, the conformation of
the fibril is adopted in a templated manner through seeded aggregation (137, 138).
Proteins that contain sequence variation, either between species or due to polymorphisms
within a species, may also be recruited by prions if common permissible conformations
exist (139). In cases where sequence variation between fibril and monomer prevents a
monomer from being recruited, transmission of the misfolded prion protein is prevented
and a barrier between divergent sequences exists (138). Transmission barriers in prions
have been observed between species and can be introduced by minor mutations (137).
The incompatibility of cross-seeded aggregation between sequences with minor
differences is not limited to prions but includes other amyloids as well. Amyloids formed
by sequences of the OsmB membrane associated protein were shown to be capable of
seeding monomer of the same sequence, but not monomers with subtle sequence
variations (140). Fibrils of α-synuclein are capable of seeding the growth of monomeric
α-synuclein, but are not capable of seeding - and -synuclein, despite having a
substantial sequence homology (141). Additionally, barriers between lysosome fibrils
have also been demonstrated between species (142). In our experiments that cross-seed
3R tau with 4R tau we demonstrate the existence of a barrier similar to what has been
observed for other amyloids. The barrier was proven to be robust, as even a 5-fold
addition (15%) of 4R fibril seeds did not allow for the recruitment of 3R tau monomer.
To verify the seeding properties between 3R and 4R tau we utilized several experimental
approaches. From our kinetics experiments, using the intrinsic reporter acrylodan and the
extrinsic fluorophore thioflavin T, as well as by electron microscopy and fibril
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sedimentation experiments we found that 3R tau does not assemble on 4R tau fibril seeds.
The seeding properties we observe in the in vitro experiments are also in agreement with
cellular studies that focused on the aggregation induced by fibril seeds. When 4R tau
fibril seeds were transfected into cells overexpressing 4R tau, the monomer was observed
to aggregate. However, transfected 4R tau fibrils into cells overexpressing 3R tau did not
result in the aggregation of the endogenous tau (49). Despite containing a majority of the
4-repeat sequence, the lack of 30 amino acids leads to an incompatibility for 3R tau
recruitment by 4R tau fibrils. Interestingly, we observed the ability of 4R tau to be
competent for the recruitment by 3R fibril seeds. This is in agreement with Clavaguera et
al. who showed that brain extracts from Pick’s disease—which contain aggregated
deposits of predominantly 3R tau—were able to induce the formation of 4R tau in
transgenic mice (55).

The cross-seeding asymmetry that we demonstrate is not the first

observed between tau fibrils. When studying the cross-seeding of fibrils composed of
disease mutant P301L tau and wild-type tau, it was shown that fibrils of P301L are
competent to seed P301L but not wild-type monomer. Alternatively, fibrils composed of
wild-type tau seed both wild-type and P301L tau, establishing an asymmetric barrier
(143).
Elongation of amyloid fibrils occurs through the subsequent addition of soluble
protein. The conformational influence that the fibril seed has on the conversion of
monomer has been demonstrated in prions and reveals that the seed conformation is
imprinted onto the assembling monomer. The robustness of the templating nature was
tested when distinct prion strains were propagated through multiple steps, with the
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resulting fibrils maintaining the strain identity of the initial seed (144). Conformational
variation is implicit in prion amyloids and is manifested in the prion seeding properties.
Prions composed of the same protein sequence can have different conformations, which
may diverge in the ability to recruit a given sequence of monomer (145). When crossseeding prions of different species, variations in sequence can prevent adoption of the
misfolded conformer from one species to another. For instance, an asymmetric seeding
barrier was observed between mouse and Syrian hamster prions that allowed the hamster
fibrils to seed mouse, but prevented mouse fibrils from seeding hamster. When mouse
monomer was seeded with hamster fibrils the resulting mouse fibrils were then capable of
seeding mouse monomer (138). The circumvention of the transmission barrier between
mouse fibrils and hamster monomer through the templating of mouse monomer on
hamster fibrils resulted in the emergence of a new conformation of mouse fibril. From
the seeded growth, mouse monomer was found to assume the conformation of the
hamster fibrils (137).
We had hypothesized that the same principles governing the propagation of prion
conformation could be applied to tau fibrils. In our experiments we analyzed the seeding
properties of 3R and 4R tau and observed an asymmetric barrier, similar to what was
shown to exist between mouse and hamster prions.

This observation provided the

opportunity to assess the parallels between tau and prion fibrils with respect to a common
conformational templating mechanism. When growing 4R tau monomer on 3R tau
fibrils, the 4R tau assumed the 3R tau fibril conformation and the resulting fibrils
permitted the recruitment of 3R tau monomer. Importantly, when multiple steps of
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propagation were performed to remove the initial 3R tau seed, the 3R tau seeding
properties were maintained within the 4R tau fibrils as indicated by the ability of the
templated 4R tau fibrils to seed 3R tau. This finding was important as it indicates that tau
and prion fibrils propagate via a common mechanism despite sharing no similarity in
sequence. In view of our findings it would be interesting to determine whether the barrier
observed preventing disease mutant P301L from seeding wild-type tau could be bypassed
when templating P301L mutant monomer on wild-type tau seeds.
The adaptation of the 4R tau monomer to the 3R tau fibril conformation indicates
that the same sequence of tau is capable of assuming different conformations that possess
variable seeding properties (i.e. one conformation that seeds 3R tau monomer and one
that does not). The ability of a tau sequence to assume variable conformations was also
demonstrated by Frost et al., who observed that 4R tau grown on distinct fibril seeds
produces different conformations (47).

The conformational diversity observed in tau

fibrils is reminiscent of the strain phenomenon observed in prions.
From our in vitro experiments we have identified at least four conformationally
distinct fibrils based on the corresponding seeding properties (Figure 6.1).

Electron

paramagnetic resonance spectroscopy studies that measure intramolecular distances
within a fibril have indicated that the conformational basis of fibrils is even more
complex, and that within a fibril sample multiple conformations can exist (63). The
effects of mutations, cofactors, chaperones, and post-translational modifications such as
phosphorylation could also influence the conformational variability of tau fibrils. In our
experiments we have demonstrated the ability of tau fibrils to seed monomeric tau,
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propagate, and diversify into different conformations. We also identified the existence of
conformational barriers that impart significant consequences on isoform recruitment. As
we have demonstrated that fibril seeds can act to provide nuclei to recruit monomeric tau,
it is therefore expected that the initial nucleation events leading to aggregation would
have a profound effect on the subsequent fibril formation. Nuclei that contain both 3R
and 4R tau, as was previously demonstrated (62), could be relevant to Alzheimer’s
disease, where all 6 isoforms are found to deposit (146).

Nucleation events of 4R tau

could be reflective of what is observed in tauopathies like progressive supranuclear palsy,
argyrophillic grain disease, and corticobasal degeneration, where 4R tau is found to
deposit (41). Based on our findings the preferential deposition of 3R tau in Pick’s disease
could not be explained by a barrier that prevents 4R tau from growing on 3R tau fibrils,
as we have demonstrated that 3R tau nuclei do seed 4R tau. However, one explanation
for the lack of 4R tau in Pick’s disease could be that another 3R tau fibril conformation
exists that does not seed 4R tau. Alternatively, it is possible that the inefficient growth of
4R tau on 3R tau fibrils, as we observe, could leave the fibrils susceptible to cellular
clearance. Our findings presented here have provided basic insights into the molecular
mechanisms responsible for tau fibril propagation. Attributes of prions such as strain
diversity, transmission barriers, and strain emergence are clearly inherent in tau fibrils,
suggesting that similar phenomena might occur in tauopathies.

99

Figure 6.1: Templated fibril growth of tau. Monomers of 3R and 4R tau (top) can
only grow onto the ends of 3R (square), 3R/4R (oval), and 4R fibrils (triangle and
hexagon) if their sequence is compatible with the conformation of the seed (arrows).
Structural incompatibility gives rise to a seeding barrier (crossed out arrow). Two
conformations are possible for 4R fibrils based on the capacity to seed 3R tau. The
conformations observed could be reflective of conformations in disease that would create
preferences for isoform deposition. PID = Pick’s disease, AD = Alzheimer’s disease, PSP
= progressive supranuclear palsy, CBD = corticobasal degeneration, AGD = argyrophilic
grain disease.

6.2 Tau cofactors bind and sustain fibril propagation
6.2.1 Fibril core is retained with diverse cofactors
The structural core of in vitro formed tau fibrils has been well characterized when
utilizing the cofactor heparin to induce fibril formation (60-62, 147). We have further
analyzed the effects of alternative cofactors on the structure of tau. Using the singlestranded poly(A) RNA nucleic acid as a cofactor, we formed aggregates with tau spin100

labeled in the third repeat, and observed single-line spectra by EPR at six different sites.
Single-line spectra were also observed at sites labeled in the third repeat when using
heparin (60, 62). The single-line spectra indicate a close proximity among the spin-labels
in the fibril. Importantly, the distance constraint implicit by a single-line spectrum
narrows the structure of the fibril core to stacked -sheeets that are parallel, with sidechains positioned in-register.
From our EPR analysis we observed that tau aggregates formed from poly(A)
RNA are highly-ordered and contain a structural core containing the third repeat that is
also found to exist in heparin induced fibrils. The ability to promote parallel, in-register
fibrils was also observed for other cofactors such as single-stranded pyrimidine RNA,
double-stranded RNA, DNA, tRNA, RNA extracted from yeast, and polyglutamate. We
demonstrate that a diverse set of nucleic acids and peptide cofactors all produce fibrils
with a structured third repeat, suggesting that the third repeat invariability remains
structured. This structural arrangement is therefore consistently conserved within tau
fibrils and does not appear to vary according to the cofactor used. The herein described
secondary structure is not limited to tau fibrils, as parallel, in-register -sheet
arrangements have also been found to be the structural basis of other amyloids (148-150).
6.2.2 Seeding properties conserved using RNA as cofactor
When using heparin as a cofactor to form fibrils we had previously determined
the seeding properties of tau and observed an asymmetric barrier between 3R and 4R tau
(120). As the cofactor initiates the formation of fibrils through nucleation, we had
speculated that alternative cofactors could produce different conformations of fibrils that
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might be reflected in variations in the seeding properties of 3R and 4R tau. The seeding
properties of tau using poly(A) RNA as a cofactor did not deviate from experiments using
heparin. The consistency of the seeding properties of tau, even when using a different
class of cofactor, suggests a robust nature of tau propagation according to isoform. While
the seeding properties remained unchanged when using a different cofactor, we cannot
exclude that poly(A) RNA produces fibrils with conformations different from fibrils
formed in the presence of heparin. It still remains possible that utilizing alternative
cofactors such as RNA could result in conformational variations that are manifested in
differences in -sheet packing.
The method for determining the seeding properties utilized our developed
acrylodan conjugated assay. The study of tau aggregation in the presence of nucleic acid
cofactors is hampered by the inability to utilize the routinely employed thioflavin assay.
Thioflavin T has been shown to bind to nucleic acids and produce enhancements in
fluorescence (151) that could be mistaken for the detection of amyloids. The use of the
acrylodan assay in these experiments further demonstrates its utility for measuring tau
aggregation.
6.2.3 Cofactor promotes elongation of fibril
Cofactors function to facilitate tau aggregation by promoting nucleation. In our
seeding experiments we introduced sonciated pre-formed fibril seeds that allow the
nucleation phase of aggregation to be bypassed. The introduction of seeds provides the
nuclei needed for aggregation and leads to the recruitment of monomer to elongate the
fibril. When studying the in vitro aggregation of tau, cofactors can be employed to
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induce fibril assembly. However, it is difficult to differentiate fibril growth phases of
nucleation and elongation. As seeding experiments result in the elongation of the fibril,
we were able to monitor fibril growth and determine whether the presence of a cofactor
contributed a role in elongation. From our multi-step seeding experiment we observed
that the propagation of fibril seeds was sustained through successive seeded reactions
only when a cofactor was provided. This result suggests that the cofactor not only
initiates the nucleation of tau aggregation, but once nucleated, also facilitates the
elongation of the fibril.

Our kinetic experiments monitoring the seeded aggregation of

tau also support this conclusion, as the addition of both seed and cofactor promoted the
assembly of tau fibrils, while the addition of only the seed did not. As incubating the
same concentrations of tau and RNA within the same time-period did not result in
aggregation we can eliminate the possibility that nucleation was occurring within the time
period and confirm that the cofactor significantly promotes the elongation of the fibril.
Our findings suggest that a “nucleation only” role for cofactors as proposed previously
(102) can be excluded.
Our results are in agreement with Zhu et al. who found that increasing the
concentration of heparin (up to a 1 heparin to 1 tau molar ratio), leads to an acceleration
in the growth phase of the aggregation kinetics.

Consisted with our findings, this

observation suggested that heparin facilitates fibril elongation (99). The effect of a
cofactor on tau fibrils also parallels the cofactor contribution to prion amyloids. When
using RNA as a cofactor, Deleault et al. showed that the successive seeding of prion
fibrils is sustained through the addition of cofactor, but lost when the cofactor is removed
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(121). While our experiments indicate that a cofactor promotes fibril elongation and
sustains aggregation, it has been shown that fibrils can be formed with high
concentrations of tau or at high temperatures without the presence of a cofactor (89, 124).
Fibrils formed without cofactor could be expected to have conformations that deviate
from fibrils formed in the presence of cofactor. It is possible that fibril conformations
nucleated without a cofactor may experience little or no reliance on a cofactor for the
elongation of the fibril.
6.2.4 Cofactor stabilizes fibrils through binding
At an elevated temperature we demonstrated that fibrils could be formed with and
without the addition of cofactor (124). A ~20 nm blueshift in the acrylodan emission
maximum after 80 minute incubation,indicated protein aggregation. The presence of
fibrilar structures was confirmed by EM imaging. When cooled, however, the fibrils
formed without cofactor were found to dissociate, while the fibrils formed with added
cofactor did not.

This observation indicated that the cofactor provides a role in

stabilizing the fibril, preventing reversion to the initial monomeric state. If the cofactor
stabilizes the fibril then it could be expected that the cofactor would bind as an accessory
component. We formed fibrils with RNA as a cofactor and carried out sedimentation
experiments to determine whether the RNA co-sedimented with the insoluble fibrils. We
observed that the majority of the RNA was found bound to the fibrils. The interaction
between the tau fibrils and the cofactor has been previously investigated, however,
reports deviate on whether the cofactor binds and is therefore part of the fibril (100-102).
Importantly, our results demonstrating the binding of cofactor to tau fibrils are in
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agreement with observations of aggregated tau found in disease. In NFTs found in
Alzheimer’s disease, the abundance of glycosaminoglycans is well documented (152156), and glycosaminoglycans have furthermore been shown to be localized on the fibrils
(155, 156). The use of nucleic acids as cofactors, as we have utilized here, is also
comparable to potential cofactors that would be found available in the cell. The inclusion
of RNA in NFTs has been shown to occur, which again suggests the occurrence of
cofactor binding to fibrils in vivo (157). The RNA found in NFTs was not characterized
according to type (tRNA, mRNA, etc), but based on our findings we demonstrate an
indiscriminant requirement for nucleic acids in the facilitation of tau aggregation. As we
have shown that poly(A), poly(U), poly(dA), poly(AU), tRNA, and RNA extracted from
yeast all are capable of forming highly ordered aggregates, the potential cofactors in the
cell are likely to be based more on availability than on specific structure.
The observation that a broad class of polyanionic molecules facilitates the
aggregation of the highly basic region of tau suggests that the binding event between tau
and cofactor occurs through electrostatic interactions.

In reactions where tau was

nucleated with the presence of a cofactor the application of elevated salt inhibited
aggregation (105, 158).

If the electrostatic interactions occurring between tau and

cofactor were limited to the nucleation phase, then elevated salt should not affect the
elongation of the fibril. When treating seeded reactions with elevated salt we observed
the abolishment of fibril growth suggesting that the cofactor-tau interactions are not
limited to nucleation events, but are also important for fibril elongation. The prevention
of fibril elongation is even expected, since we have shown that cofactors bind to fibrils.
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Disrupting the electrostatic interactions by introducing high salt would therefore inhibit
binding and prevent aggregation as was observed.
6.2.5 Cofactor exchange on the fibril
When using RNA as a cofactor to induce tau aggregation we have observed the
incorporation of the cofactor into the fibrils.

As we had used truncated constructs

containing the binding repeats, the binding event is likely to occur at or near the fibril
core and not at the unstructured N- and C-termini.

We had asked whether the

introduction of another cofactor could exchange the cofactor originally used for
induction.

When heparin was incubated with fibrils with bound RNA, the co-

sedimentation of RNA with the insoluble aggregates no longer occurs, indicating the
removal of the RNA from the fibrils had taken place. The assumption that the RNA
removal occurred through the exchange of heparin was verified when fluorescein
conjugated heparin was used as the exchanging cofactor. The dye-labeled heparin was
found to cause the release of the RNA from the fibril and was found to be associated with
the sedimented aggregates.

Also, the increase in the fluorescence anisotropy of the

fluorescent heparin was observed with the addition of RNA induced fibrils, further
confirming the effect of cofactor exchange.
The observation that cofactors can exchange on the fibril is important, as it
indicates that the binding of the cofactor to the fibril does not occur at a buried site, but
instead binds at a region that would be accessible for cofactor exchange. The cofactor
therefore would be expected to bind on the surface of the fibril. Based on tau fibril
structure, the orientation of tau strands in the fibril would require side-chains to be
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stacked on top of each other. As the repeat region of tau fibrils is highly basic, the
resulting fibril structure would require positively charged side-chains to be positioned in
close proximity. Specifically, in repeats two and three, where tau is highly structured,
there are five and four lysines present, respectively, that would introduce charge
repulsions between parallel stacked -strands. The binding of the polyanionic cofactor
could neutralize these repulsions and stabilize the fibril. It would seem probable that the
cofactor-tau binding occurs with the length of the cofactor polymer stretched along the
long fibril axis, similar to what has been observed for DNA bound to α-synuclein fibrils
(159). In this manner the cofactor could act as a scaffold to bridge and neutralize the
positive repulsions between multiple strands of tau. As was shown by the replacement of
RNA by heparin, cofactors are not bound statically, but are dynamic and can exchange on
the fibril (Figure 6.2). The binding of cofactor to tau could have significant implications
for the fibril properties. Namely, the decoration of fibrils by varying cofactors could
affect the fibril surface and impart the ability to transfer between cells. Proteoglycans
have been shown to be distributed on the cell surface (160) and could be a means by
which tau fibrils could transfer into cells. Based on heparin exchange with RNA on the
fibril, we have shown that tau fibrils can bind glycosaminoglycans through an exchange
mechanism.

As proteoglycans have been shown to bind cationic ligands such as

polypeptides and provide a role of endocystosis (161), it is possible that the same
internalization mechanisms may be applied to tau fibrils. In fact, cell surface heparan
sulfate proteoglycans have recently been shown to facilitate the cellular binding and
internalization of tau fibrils (162).

These findings further indicate the importance
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inherent in the tau-cofactor association. It is possible that cofactors bound to tau fibrils
could exchange for proteoglycans on the cell surface, providing a mechanism for the
internalization of tau fibrils into the cell, which ultimately could account for the
spreading of the tau pathology.

Figure 6.2: Cofactor binding and exchange on the fibril. The envisioned mode of
cofactor binding is that a cofactor polymer such as poly(A) RNA could bind along the
fibril and neutralize repulsive positive charges introduced from side-chain proximity
between strands. The introduction of a cofactor such as heparin can result in the
exchange of the bound cofactor.
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6.3 Tau fibril amplification by PMCA
From our in vitro experiments we have demonstrated that we can transcend the
limitations of low seed concentrations when carrying out seeded reactions of tau. For the
first time we have applied the principles of PMCA used to amplify prions towards the
amplification of tau fibrils.

As shown by the thioflavin T assay, and verified by

sedimentation of fibrils, we have successfully propagated fibrils whose concentration was
shown previously to be too dilute for efficient seeded amplification. Next, we assessed
the sensitivity of seed dilution and found that we could amplify a concentration of seed
diluted 104 fold of what was found to be insufficient to recruit monomer effectively in a
single sonication cycle seeded reaction (0.1% seed). At this concentration (0.00001%
seeds) tau in the fibrils is present at 108 molecules ( 5 X 108 molecules per mL), while the
total tau monomer (10 µM) consists of 1015 molecules. Whether we had used seeds of
truncated (K18) or full-length (htau40) tau to amplify, similar sensitivity was observed.
Htau40 WT was the recruited monomer in all of the experiments. As truncated tau
nucleates to form aggregates in a shorter time period than full-length tau (163, 164), we
would not have been able to apply as many PMCA cycles before the monomer only (no
seeds) negative controls would have begun to aggregate. Therefore, by using htau40
monomer to be recruited we were able to perform more cycles (40 cycles), and
meanwhile avoid spontaneous nucleation. Since the monomer only (no seeds) was never
shown to aggregate during the 40 cycles, we can be confident that the fibril growth
observed through the addition of seeds is not due in part to monomer nucleation, but
solely to the elongation and propagation of the fibril seeds. Induced aggregation of tau
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monomers is best promoted under conditions of low salt (0.1M NaCl) (158) and is aided
by oxidizing conditions when native cysteines are present (96). Additionally, full-length
tau may take days to aggregate at low µM concentrations (4-50 µM) at 37 °C (96).
Attention to the applied conditions is therefore important when considering the
prevention of spontaneous nucleation of monomer.
In the PMCA reactions carried out, the cofactor heparin was added.

When

cofactor was not included we found that the amplification efficiency was drastically
reduced, regardless of whether K18 or htau40 were used as seeds. This finding was
expected as we had previously shown that the addition of a cofactor was needed for the
fibril propagation to be sustained.

Interestingly, when PMCA is applied to prion

amyloids it has been shown that the fibril amplification is also dependent on the presence
of a polyanionic cofactor (121, 165), further suggesting common requirements needed for
growth of both tau and prion fibrils.
The incubation and breakage (sonication) steps are believed to be the basis of
amplification when PMCA is applied to prions. In fact, PMCA applied to prions without
the incubation steps (166) or without the sonication steps (109, 166, 167) results in a loss
of amplification. Similarly, we found that a reaction, in which the fibrils were only
sonicated 1 cycle (5 seconds) and incubated for 20 hours were not substantially
amplified. Reactions in which all the sonication steps were carried out consecutively
(40 cycles, 200 seconds) and incubated for 20 hours also did not result in
considerable amplification. This observation indicates the need for sonication steps to be
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spaced between the incubation steps, in order to allow time for fibril elongation to occur
before the next breakage step is induced.
Our findings presented here indicate that PMCA can be applied to the
amplification of dilute quantities of tau fibrils.

The function of this assay could

ultimately be applied towards the amplification of tau fibrils derived from biological
samples. When applied to prions, PMCA has been used to quantitatively determine the
concentration of prions within a sample. Using animal models the PMCA assay has
demonstrated a heightened sensitivity that allows for the detection of dilute prion
concentrations in sources that include brain, blood, and urine (168, 169). Similarly it is
possible that PMCA could provide a diagnostic tool for the presence of tau fibrils found
in comparable tissue and fluid samples. We have taken the first important steps to
optimize an assay and implement PMCA for the amplification of tau fibrils. The utility
of PMCA applied to tau fibrils is expected to support fundamental studies of fibrils
derived from in vivo sources.
6.4 Future work
The described studies were performed using recombinant tau protein that was not
phosphorylated. As phosphorylation of tau is associated with disease, further studies are
needed to elucidate whether phosporylation of tau is critical for the phenomena observed.
For example, it is not known whether the seeding properties of tau fibrils are influenced
by tau phosphorylation. We observed that fibril propagation is dependent on the presence
of a cofactor.

As phosporylation assists in the aggregation of tau (85), it will be

important to determine whether phosporylated tau requires cofactors for template growth.
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Finally, we have developed an assay for the amplification of tau fibrils.

Further

optimization is needed to enhance its sensitivity and to adopt it for use in conjunction
with in vivo derived material.
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Appendix A: Tau constructs

Repeat Region of tau

MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEDGSEEPG

60

SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHTEIPEG TTAEEAGIGD TPSLEDEAAG

120

HVTQARMVSK SKDGTGSDDK KAKGADGKTK IATPRGAAPP GQKGQANATR IPAKTPPAPK

180

TPPSSGEPPK SGDRSGYSSP GSPGTPGSRS RTPSLPTPPT REPKKVAVVR TPPKSPSSAK

240

SRLQTAPVPM PDLKNVKSKI GSTENLKHQP GGGKVQIINK KLDLSNVQSK CGSKDNIKHV

300

PGGGSVQIVY KPVDLSKVTS KCGSLGNIHH KPGGGQVEVK SEKLDFKDRV QSKIGSLDNI

360

THVPGGGNKK IETHKLTFRE NAKAKTDHGA EIVYKSPVVS GDTSPRHLSN VSSTGSIDMV

420

DSPQLATLAD EVSASLAKQG L

QTAPVPMPDLKNVKSKIGSTENLKHQPGGGK

Repeat 1

VQIINKKLDLSNVQSKCGSKDNIKHVPGGGS

Repeat 2

VQIVYKPVDLSKVTSKCGSLGNIHHKPGGGQ

Repeat 3

VEVKSEKLDFKDRVQSKIGSLDNITHVPGGGN

Repeat 4

*cysteines found in repeat 1 and 2

127

Htau40
MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKESPLQT PTEDGSEEPG

60

SETSDAKSTP TAEDVTAPLV DEGAPGKQAA AQPHTEIPEG TTAEEAGIGD TPSLEDEAAG

120

HVTQARMVSK SKDGTGSDDK KAKGADGKTK IATPRGAAPP GQKGQANATR IPAKTPPAPK

180

TPPSSGEPPK SGDRSGYSSP GSPGTPGSRS RTPSLPTPPT REPKKVAVVR TPPKSPSSAK

240

SRLQTAPVPM PDLKNVKSKI GSTENLKHQP GGGKVQIINK KLDLSNVQSK CGSKDNIKHV

300

PGGGSVQIVY KPVDLSKVTS KCGSLGNIHH KPGGGQVEVK SEKLDFKDRV QSKIGSLDNI

360

THVPGGGNKK IETHKLTFRE NAKAKTDHGA EIVYKSPVVS GDTSPRHLSN VSSTGSIDMV

420

DSPQLATLAD EVSASLAKQG L

441

Estimated pI = 8.24
M.W = 45850
Htau23
MAEPRQEFEV MEDHAGTYGL GDRKDQGGYT MHQDQEGDTD AGLKAEEAGI GDTPSLEDEA
AGHVTQARMV SKSKDGTGSD DKKAKGADGK TKIATPRGAA PPGQKGQANA TRIPAKTPPA
PKTPPSSGEP PKSGDRSGYS SPGSPGTPGS RSRTPSLPTP PTREPKKVAV VRTPPKSPSS
AKSRLQTAPV PMPDLKNVKS KIGSTENLKH QPGGGKVQIV YKPVDLSKVT SKCGSLGNIH
HKPGGGQVEV KSEKLDFKDR VQSKIGSLDN ITHVPGGGNK KIETHKLTFR ENAKAKTDHG
AEIVYKSPVV SGDTSPRHLS NVSSTGSIDM VDSPQLATLA DEVSASLAKQ GL

Estimated pI = 9.38
M.W = 36760
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K18 Construct
MQTAPVPMPD LKNVKSKIGS TENLKHQPGG GKVQIINKKL DLSNVQSKCG SKDNIKHVPG
GGSVQIVYKP VDLSKVTSKC GSLGNIHHKP GGGQVEVKSE KLDFKDRVQS KIGSLDNITH
VPGGGNKKIE

Estimated pI = 9.7
M.W = 13813
K19 Construct

MQTAPVPMPD LKNVKSKIGS TENLKHQPGG GKVQIVYKPV DLSKVTSKCG SLGNIHHKPG
GGQVEVKSEK LDFKDRVQSK IGSLDNITHV PGGGNKKIE

Estimated pI = 9.67
M.W = 10567
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Appendix B: Tau purification

Elution program and gradient profile
Mono S 10/100
GL
Flow rate
(ml/min)
Eluate fraction size (ml)
Linear gradient
Target concentration buffer B (%B)

3.0
3.0
60.0
1

Length of gradient (column volumes)

11.0

Linear gradient for cation exchange elution of tau. Slope of increasing buffer B versus
ml of eluate.
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Htau40 WT cationic exchange elution profile

Cationic exchange elution chromatograph for htau40 WT. Absorbance at 280 nm shown
in blue with the linear gradient shown in green. Eluate fractions (3ml) shown at the
bottom in red.
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Htau40 WT gel filtration elution profile

Gel filtration elution chromatograph of Htau40 WT. Htau40 WT purified over Superdex
200 medium packed column
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Appendix C: PMCA setup

Bath sonicator horn used for applied cycles of PMCA
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PMCA reactions in 96-well plate with sample cover.
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96-well plate with cover and plate lid. Two transfer pipette bulbs were sealed and
fastened to plate to allow for plate to float in bath sonicator.

135

Covered plate was allowed to float in bath sonicator while undergoing PMCA.
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